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Abstract
This thesis contributes to the broad field of Bayesian variable selection.
Motivated by real problems in the analysis of genomic data we build new
statistical models that answer important questions and help to explain un-
derlying biological processes.
In the first project we propose a novel method that provides insights in
the analysis of genomic data in situations where the target of the analysis
is to find which genes (predictors) are related to a specific phenotype, the
response variable. Our model considers, first, that it has been clearly recog-
nized that genes are biological elements that affect each other and, second,
that recently interest in biology has moved from the analysis of single genes
to the analysis of known groups of genes, called pathways. We build upon
Bayesian variable selection methods for linear/generalized linear models by
adding two novel features into the model: first we are able to incorporate
information on gene networks in our prior formulation, second we develop
stochastic search methods that are able to identify both pathways and path-
way elements involved in particular biological processes. To achieve these
goals we define a new Ising-type prior on the latent indicators of genes in-
cluded into the model. In addition, we define pathway scores that synthesize
the activity of each pathway via partial least square techniques. We construct
a Monte Carlo Markov chain scheme with a double layer of selection indi-
cators, one for genes and one for pathways, that takes into account a set of
constraints for both identifiability of the model and biological interpretation.
The method we put forward represents a consistent framework for testing
whether a pathway is significantly related to a phenotype without using a
2-step procedure whose statistical properties, like the significance level of 2
hypothesis testing performed in sequence, would be difficult to investigate.
We use our method both with simulated data and on an application to gene
expression data with censored survival outcomes. In addition to a better un-
derstanding of the underlying molecular processes, our method also improves
on prediction accuracy.
In the second project we construct a statistical procedure to infer a bio-
logical network of very high dimensionality, where microRNAs, small RNAs,
are supposed to down-regulate mRNAs, also called target genes. The main
goal of the model is to understand which elements are connected and which
ones are not. In addition, specific biological characteristics/constraints need
to be considered. From a statistical point of view, we address this problem by
building a network that represents the biological regulatory system, indicat-
ing which microRNA regulates which gene. In particular, we provide a novel
graphical modeling approach that includes constraints on the regression co-
efficients to take into account the down-regulatory effect of the network. Our
approach is able to select single connections in the network, unlike previous
methods in the Bayesian variable selection literature, which only allow the
selection of covariates (microRNAs) that affect either all the genes or none of
them. The main challenge of this project is represented by the dimensionality
of the data. The network is potentially formed by more than 30,000 connec-
tions and the data are formed by 12 observations. By developing a stochastic
search variable selection type of algorithm we are able to efficiently explore
the space of all possible networks and to find, for each gene, which microR-
NAs have high posterior probability of being down-regulating the gene. To
help the selection, we also propose a new prior formulation which is able to
integrate different sources of data, by exploiting information from previous
sequence and structure analysis. Because we integrate many sources of infor-
mation, our model is also able to determine which information is consistent
with the data via posterior inference on the parameters defined in our data-
integration prior. The proposed method is general and can be easily applied
to other types of network inference by integrating multiple data sources.
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Chapter 1
Introduction
In this Chapter we introduce two topics, graphical models and Bayesian vari-
able selection, which will be extensively used in the following chapters. First,
in Section 1.1, we describe graphical models, both directed and undirected,
focusing on Gaussian graphical models and graphical models for binary vari-
ables. In Section 1.2 we review Bayesian approaches for variable selection in
linear models; we describe different specification for the hierarchical model
and various approaches for posterior inference, including several Monte Carlo
Markov Chain (MCMC) strategies. Finally we briefly describe the projects
that will form the following chapters, by giving a general idea of the problems
addressed and indicating the main features.
1.1 Brief Introduction to Graphical Models
Graphical models, see Whittaker (1990) and Cowell et al. (1999) among
others, are methods and techniques that use Graph Theory to model the
relationships between random variables. A graph is formed by nodes and arcs;
nodes represent random variables and the lack of arcs represent conditional
independence assumptions. Hence they provide a compact representation of
joint probability distributions. A graph is consistent with the conditional
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independence statements expressed in the distribution. However note that
it is not always possible to obtain a perfect map; this means that some
distributions characterized by specific conditional independencies cannot be
represented using a graphical model.
Arcs can be undirected (used for symmetric dependencies) or directed
(used when there is a direction in the dependence). These dependencies
can come from prior knowledge or from data analysis. Undirected graphical
models, also called Markov Random Field (MRF), have a simple definition of
independence: e.g., two sets of nodes A and B are conditionally independent
given a third set, C, if all paths between the nodes in A and B contain at
least one node belonging to C.Figure 1.1 displays an example of graphical
model. In a graph it is possible to describe the conditional independencies
among the variables using three equivalent Markov properties. The Pairwise
Markov property says that two variables that are not neighbors in the graph
are conditional independent given all the other variables. The Local Markov
property says that every variable Xi is independent of the variables not in
cl(Xi) conditional on the set of variables directly connected to Xi (boundary
of Xi), where cl(Xi), the closure of Xi, is the set of nodes formed by Xi and
its boundary. The Global Markov property says that two sets of variables B
and C that are not connected are independent given a third set of variables
S formed by all the variables that separate B and C. Some of the conditional
independencies that we can gather from figure 1.1 are:
• X1⊥⊥X4|(X2, X3, X5) - Pairwise Markov,
• X1⊥⊥(X4, X5)|(X2, X3) - Local Markov,
• (X1, X2)⊥⊥X5|(X3, X4) - Global Markov (B = {X1, X2}, C = {X5},
S = {X3, X4}).
Directed graphical models, also called Bayesian Network (BN), need a spe-
cific ordering of the variables. Since we do not allow for the presence of cycles
we work with directed acyclic graph (DAG). Conditional independencies in
7
Figure 1.1: An example of undirected graphical model
a DAG depend on the ordering of the variables. When the joint distribu-
tion is a multivariate normal the model is called Graphical Gaussian model
(GGM). The graph G and the covariance matrix Σ entirely define a GGM
M, M ≡ (G,Σ). Nodes that are directly connected to node j and precede
j in the ordering are called parents of j , pa(j). In a Bayesian Network, Xj
is independent, given its parents, of the set of all the other variables in the
graph, except its parents.
In Chapter 2 a graphical model with binary random variables is used.
This type of model, called Ising model, is widely used in statistics. An Ising
model is a system with 2p states, where p indicates the number of variables
of which corresponding graph is a lattice system. The variables xj, with
j = 1, . . . , p, can assume only two values, xj ∈ {0, 1}, and their probability
distribution is assumed to be:
P (x) =
exp(d′x+ x′Gx)
Z
(1.1)
with d = d1p, 1p the unit vector of dimension p and G a symmetric matrix
with elements {gij} usually set to some constant g; if nodes i and j are not
connected in the graph the corresponding gij is equal to zero. Z is usually
called partition function and, except for the 1-D Ising model, where each
8
node has a maximum of two neighbors, it is not possible to calculate its
value in closed form. To understand the role of the parameters d and G it is
helpful to look at the conditional probability distribution
P (xj|xi, i ∈ Nj) =
exp(xj(d+
∑
i∈Nj gijxi))
1 + exp(d+
∑
i∈Nj gijxi)
. (1.2)
The larger d the higher the probability assigned to configurations with most
of the xj’s equal to 1. Chapter 2 explains how this parameter is linked
to the concept of sparsity. The hyperparameters gij’s represent the prior
belief on the strength of coupling between the pairs of neighbors (i, j). This
parametrization has been recently used in the contest of variable selection
by Li & Zhang (2009).
A problem faced by Li & Zhang (2009) is the phase transition, that is,
the expected number of variables equal to 1 can increase massively for small
increments of G. This problem can happen because equation (1.2) can only
increase as a function of the number of xj’s equal to 1. In Chapter 2 we adopt
an alternative parametrization that has been used in statistics, at least, since
the work of Besag (1974), see also Besag (1986), and that allows us to avoid
the phase transition problem. Recently this distribution has been used by
Wei & Li (2007) and Wei & Li (2008) in the context of gene expression
analysis for a frequentist multiple hypothesis testing procedure; they refer
to this model as a Markov Random Field (MRF). Here we assume that the
global distribution on x is given by
P (x) ∝ exp(µ n1 − η n01), (1.3)
where n1 is the number of xj’s equal to 1 and n01 is the number of edges
linking variables with different values,
n1 =
p∑
j=1
xj, n01 =
1
2
p∑
i=1
[
p∑
j=1
rij −
∣∣∣∣∣
p∑
j=1
rij(1− xi)−
p∑
j=1
rijxj
∣∣∣∣∣
]
,
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where rij is the generic element of the p × p matrix R that describes edges
of the graphical model, with rij = 1 if xi and xj have a direct link in the
network, and rij = 0 otherwise. The corresponding conditional distribution
is
P (xj|xi, i ∈ Nj) = exp(xjF (xj))
1 + exp(F (xj))
, (1.4)
where F (xj) = µ+ η
∑
i∈Nj(2xi − 1) and Nj is the set of direct neighbors of
xj in the graph. The parameter µ controls the sparsity of the model, with
higher values of η encouraging neighboring variables to take on the same
xj value. For variables with no neighbors, this distribution reduces to an
independent Bernoulli with parameter p = exp(µ)/[1 + exp(µ)], which is a
logistic transformation of µ.
1.2 Stochastic Search Variable Selection
This Section is a brief introduction to the general theory of the Stochastic
Search Variable Selection (SSVS) method introduced by George & McCul-
loch (1993) in the linear regression framework and subsequently adapted to
other modeling settings by many other authors, see for example Brown et al.
(1998b) and Sha et al. (2004).
This method allows to select the “best” subset of covariates from the 2p
possible models in a linear framework where Y is the dependent variable and
X1, . . . , Xp are the potential predictors. This approach has been developed
to handle situations where the number of variables p is bigger, and often
much bigger, than the number of observations n. In such situations most
of the standard methods can not be used. Note, for example, that the ma-
trix X ′X is not invertible. By imposing a hierarchical Bayes mixture prior
on the regression coefficients, this procedure puts a probability distribution
on the set of all possible regression models and then uses a MCMC algo-
rithm (Gibbs sampler in the original paper and Metropolis-Hastings in most
of the recent papers) to ’run’ through this set. “Best” models are clearly
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those with high probability. The main property of this procedure is that, in
a high-dimensional framework, the MCMC can be used to obtain a sample
from the posterior distribution quickly and efficiently; this avoids the over-
whelming (and often mathematically or computationally impossible) burden
of calculating the posterior probabilities of all subsets.
The linear regression model is
Y ∼ Nn(Xβ, σ2In)
where Y is a n × 1 vector, X is a n × p matrix and β is a p × 1 vector
of regression coefficients. Selecting a subset of predictors is equivalent to
setting to zero the elements of β corresponding to the excluded predictors.
In the milestone paper of George & McCulloch (1993), the prior on β is
a mixture of two normal distributions, the first one with most of its mass
concentrated about zero and the second one with its mass spread out over
plausible values. Using the latent variable γi = 0, 1, the prior of each element
of β can be expressed as
P (βi|γi) = (1− γi)N(0, τ 2i ) + γiN(0, c2i τ 2i ).
The hyperparameter τi is set small and c
2
i is set large so that N(0, τ
2
i ) is
concentrated about zero and N(0, c2i τ
2
i ) is diffuse. With this prior, if γi = 0
then βi is so small that it could be estimated by 0, whereas if γi = 1 a
nonzero estimate of βi corresponds to an important predictor. In this model
the βi are independent given the vector γ = (γ1, . . . , γp). The prior on γ is
the product of p independent Bernoulli
P (γ) =
p∏
i=1
wγii (1− wi)(1−γi)
with wi = P (γi = 1). This probability can be interpreted as the prior
probability that Xi should be included in the model; the set of parameters
wi regulates the sparsity of the model, defining the a priori expected number
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of included regressors. The prior on σ2 is the conjugate Inverse Gamma
σ2 ∼ InvGa(ν/2, νλ/2)
and priors on β and σ2 are treated as independent distributions.
For posterior inference, the posterior distribution of γ,
P (γ|Y ) ∝ P (Y |γ)P (γ),
allows to identify the “best” models, that is those most supported by the
data and by the prior distribution. The main target of the Gibbs sampler is
to generate the sequence
γ(0), γ(1), γ(2), . . .
which converges in distribution to P (γ|Y ). The algorithm does not need
to explore the entire distribution to find the most probable models, because
many models have small posterior probability and can be ignored. This is
due to the idea of ’sparsity’, that relates to situations where many of the
possible relations (the coefficients in our case) are so small to be practically
zero or represent only noise. In other words, we think here of the ’true’ model
as being sparse.
The above sequence can be obtained by applying the Gibbs sampler to the
complete posterior P (β, σ2, γ|Y ); the output is the full sequence of parameter
values
β(0), σ(0), γ(0), β(1), σ(1), γ(1), . . .
a Markov chain generated by the full conditional distributions P (β|σ2, γ, Y ),
P (σ2|β, γ, Y ) and P (γi|β, σ2, γ−i, Y ), with γ−i = (γ1, γ2, . . . , γi−1, γi+1 . . . , γp).
From Figure 3.2, representing the graphical structure of the model, we see
that the choice of the prior distributions allows to obtain the full conditionals
in closed form leading to the following simplifications:
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Figure 1.2: The graphical model structure of the linear regression model.
P (σ2|β, γ, Y ) = P (σ2|β, Y )
P (γi|β, σ2, γ−i, Y ) = P (γi|β, γ−i),
since the full conditional of any node depends only on the values of its parents,
children and co-parents, where ’co-parents’ are other parents of the children
of the node (see Figure 3.2).
Smith & Kohn (1996) have extended this variable selection procedure to
semiparametric additive models reframing the problem in terms of a linear
model. The main feature of their procedure is the implicit introduction
of a spike and slab prior, explicitly introduced and analyzed by George &
McCulloch (1997), for the regression coefficients
βi|γi, σ2 ∼ (1− γ1)δ0 + γiN(0, σ2cxii),
where δ0 is a Dirac’s delta concentrated at 0 and xii is the i-th element of
the diagonal of (X ′X)−1. They then specify a g-prior on the vector of the
selected regression coefficients β|γ, σ2 ∼ N(0, σ2c(X ′X)−1), while the non-
selected β’s are excluded from the model. This setting leads to a faster
computing algorithm since we are able to integrate β and σ2 out from the
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model. The only parameter sampled in the corresponding MCMC is then
γ and, consequently, this algorithm needs to explore only the model space
represented by P (γ|Y ). Smith & Kohn (1996) used a Gibbs sampler where at
each step they sample, for i = 1, . . . , p, from the full conditional distributions
P (γi = 1|γ−i, Y ) = 1
1 + h
where
h =
1− wi
wi
(c+ 1)1/2(S(γ1)/S(γ0))n/2
and γ1 = (γ1, . . . , γi−1, γi = 1, γi+1, . . . , γp), γ0 = (γ1, . . . , γi−1, γi = 0, γi+1, . . . , γp),
S(γ) = Y ′Y − c
1+c
Y ′X(X ′X)−1X ′Y .
After obtaining a sample from the posterior distribution of γ given the
data D, and the associated posterior probabilities P (γ|D), two strategies for
posterior inference are possible. The first approach uses only the model with
the highest posterior probability, while the second approach, proposed by
Madigan & Raftery (1994) and Madigan & York (1995), uses a set of models
with high posterior probability. This set can include all the models visited in
the MCMC; this procedure gives a good approximation of the marginalization
over every possible model and is directly linked to an exploration algorithm of
the model space. Madigan & York (1995) propose a method, in the context of
model selection for discrete graphical models, to perform posterior inference
for a quantity of interest ∆ under model uncertainty. Because the procedure
is not specific to the selection of a regressor in a linear model they do not use
the parameter γ but indicate with Mk one of the possible models belonging
to class of models under consideration M. The model averaging posterior
inference for ∆ under model uncertainty is then performed using:
P (∆|D) =
K∑
k=1
P (∆|Mk, D)P (Mk|D). (1.5)
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This formula averages the posterior distribution under each of the mod-
els weighted by their posterior probabilities. To obtain the probabilities
P (Mk|D), at least for a significant subset of models, Madigan & York (1995)
propose a procedure called Markov Chain Monte Carlo model composition
(MC3). Integrating out all the parameters and defining, implicitly, a flat
prior on the model space, the MC3 consists of a Metropolis-Hasting algo-
rithm to explore the posterior distribution P (M |D), where at each step a
new model, that differs from the model selected at the previous step only for
the inclusion or exclusion of an edge, is proposed.
Brown et al. (1998a) adapted and perfected the MC3 algorithm in the
context of linear regression. Starting from a parametrization similar to Smith
& Kohn (1996), after integrating out the model parameters β and σ2, it
is possible to define an MC3-type procedure for γ. First a value for γ is
randomly chosen and then moves through a sequence of further values of γ are
performed, with each step in the sequence having an element of randomness.
At each point in the sequence a new candidate γ is generated by randomly
modifying the current one. If the new candidate has a higher probability
than the current one, then the chain will move to the new configuration γ′.
If not, then the move is still possible, but now only with a certain probability.
This feature explains why this algorithm is also called random search. Brown
et al. (1998a), specifically, define two types of moves:
1. (Adding or deleting) Choose one of the p covariates at random. If
the variable is currently in the model, delete the variable; if it is not
currently in the model, add it to the model. Thus the new candidate
γ′ differs from the previous γ in one of its entries.
2. (Swapping) Choose at random one of the currently included variables
and at random one of the currently excluded covariates. Exclude the
previously included variable from the candidate model and include the
previously excluded covariate.
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By indicating with g(γ) = P (γ)P (Y |X, γ), the new candidate model γ′
is accepted with probability
min
[
g(γ′)
g(γ)
, 1
]
.
Note that the proposal distribution associated to this MCMC scheme is sym-
metric and does not appear in the acceptance ratio. In every model where
it is possible to integrate out all the parameters but γ, this Metropolis algo-
rithm is preferred to the Gibbs sampler because it allows a faster exploration
of the space of the relevant models.
Several different MCMC schemes have been proposed to achieve a faster
exploration of the posterior distribution P (γ|Y ). Recently Bottolo & Richard-
son (2009) have proposed and evolutionary Monte Carlo scheme combined
with a parallel tempering approach that allows the algorithm to explore the
model space faster by avoiding to remain stuck in local modes. Beside the
different ideas combined in Bottolo & Richardson (2009), an interesting fea-
tures of their algorithm is that they use an efficient Gibbs sampling. In
Bayesian variable selection the Metropolis algorithm of Brown et al. (1998a)
is usually preferred to the Gibbs sampler because, using the latter, at each
iteration the algorithm has to go through all the full conditionals of every
variable indicator, sampling each element of the vector γ. Therefore most
of the non selected variables at the previous step will not be included into
the model because completely unrelated to Y . Bottolo & Richardson (2009)
have built an MCMC scheme that does not need to sample all the indicators
at each step, skipping a lot of heavy computations related to non significative
variables.
Brown et al. (1998b) have generalized the SSVS to multivariate regression
model with q response variables. Defining the SSVS procedure requires the
introduction of matrix variate distributions. Following Dawid (1981), the
notation Y −M ∼ N (Γ,Σ) indicates a n×q normal matrix-variate whereM
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indicates the mean and γiiΣ and σjjΓ indicate the covariance matrices of the
i-th row and j-th column, respectively. The data model, with p covariates, q
response variables and n independent samples can be defined as Y − 1α′ −
XB ∼ N (In,Σ). Using the following priors
α− α0 ∼ N (h,Σ)
B−B0 ∼ N (H,Σ)
Σ ∼ IW(δ,Q)
it is possible to integrate all three parameters out from the model. This fea-
ture, jointly with a QR deletion-addition algorithm for fast updating in the
calculation of the marginal likelihood, leads to a very efficient Gibbs MCMC
scheme for posterior inference. Note that Brown et al. (1998b) specify a la-
tent p × 1 vector indicator for the inclusion of the covariates, with the j-th
element equal to 1 if the j-th covariate is significant for all q response vari-
ables. Consequently, it is not possible to define different sets of significant
covariates for different response variables. Moreover, Brown et al. (1998b)
use the model averaging idea of Madigan & York (1995) for prediction of
new observations Yf . This procedure is based on the predictive distribution
p(Yf |Y,Xf ) and exploits the conjugacy of the model; after integrating α, B
and Σ out it is possible to calculate Yf as weighted mean of the expected val-
ues of p(Yf |Y,Xf ) given different configurations of γ, with the weights being
the posterior probabilities of these configurations. Only the best k configu-
rations, according to the posterior probabilities, are used for prediction.
1.3 Description of the Projects
This thesis is composed by two different projects that share some basic fea-
tures:
1. They are motivated by new challenges in the analysis of genomic data;
2. They relate to Bayesian models for variable selection;
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3. They are built for p much bigger than n problems;
4. They integrate different sources of data.
In Chapter 2, starting from the classical problem of finding genes that relate
to a response variable, we build a model that takes into account both the
dependence structure among the genes and the fact that genes usually work
in groups, called pathways. Gene selection is important for disease diagnosis
and therapeutic target selection. However, gene selection alone may not
be sufficient. For example cancer drugs are increasingly designed to target
specific pathways. The identification of critical genes and pathways in disease
development is one of the most important tasks in the post-genomic era.
Most of the available methods make inference about pathways using a
two step procedure where at the first step the significant genes are selected
and, at the second step, a test statistic for the detection of the significant
pathways is calculated based on the previously selected genes. Because of
the two-steps nature of these procedures, it is not possible to determine the
real significance level of the tests.
We propose a model that incorporates biological knowledge from pathway
databases into the analysis of DNA microarrays to identify both pathways
and genes related to a phenotype. In our model information on pathway
membership and gene networks is used to define pathway summaries, to
specify prior distributions that account for the dependence structure between
genes, and to define the MCMC moves to fit the model. The group behav-
ior of genes in pathways is summarized using the first PLS (Partial Least
Squares) latent component obtained from the genes in each of the pathways
included into the model. PLS allows us to extract, from every pathway, most
of the information that explains the response variable. The gene network
information is modeled using a Ising-type Markov Random Field prior on
the binary selection indicators of the genes.
The employment of the gene network prior and the synthesis of the path-
way information through PLS bring additional information into the model
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that is especially useful in microarray data, where there is low sample size
and large measurement error. We evaluate the performance of the method
using simulated data. We also illustrate the method on a breast cancer gene
expression dataset with survival outcomes. We show that our model can lead
to the selection of significant genes that would have been missed otherwise.
In addition we achieve better prediction results compared to models that
do not treat genes as connected elements that work in groups or pathways.
Chapter 2 is entirely derived from a paper written together with Yian A.
Chen (Moffit Cancer Center), Mahlet G. Tadesse (Georgetown University)
and Marina Vannucci (Rice University); this manuscript is a technical report
(TR2010-01) of the Department of Statistics at Rice University and it has
been submitted to the Annals of Applied Statistics.
In Chapter 3 we describe how to infer a regulatory network where genes
are supposed to be regulated by microRNAs (an abundant class of small,
∼22 nucleotide, RNAs). The motivation of this work comes from one of the
main questions in genomics: What functional relationships exist among genes
and how are they influenced by other biological elements? This question can
be appropriate in many situations. Our first problem is to understand the
regulatory process of microRNAs (miRNAs) on the genes (miRNA targets).
Because of the usual lack of samples we use external information that helps
finding significant connections between genes and miRNAs. Specifically, we
use a directed graphical model (Bayesian Network) with a predetermined or-
dering of the nodes based on biological considerations and use the Bayesian
paradigm for inference. This model is able to answer to the baseline question
of ’which miRNAs regulate which targets ’ and allows us to build a fast compu-
tational procedure required in a high-dimensional framework. The challenge
of the analysis is in building a fast computational procedure which is able
to find sets of most probable models (that is, a model selection problem).
We use a stochastic search variable selection type procedure adapted to a
high-dimensional graphical model with prior distributions reflecting biologi-
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cal information. Chapter 3 is entirely derived from a paper written together
with Yian A. Chen (Moffit Cancer Center), Marina Vannucci (Rice Univer-
sity), Marianne Barrier (Texas A&M University) and Philip E. Mirkes (Texas
A&M University); this manuscript is a technical report (TR2009-01) of the
Department of Statistics at Rice University and has been invited for revision
by Annals of Applied Statistics.
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Chapter 2
Bayesian Models for Pathway
and Gene selection
The vast amount of biological knowledge accumulated over the years has
allowed researchers to identify various biochemical interactions and define
different families of pathways. There is an increased interest in identifying
pathways and pathway elements involved in particular biological processes.
Drug discovery efforts, for example, are focused on identifying biomarkers as
well as pathways related to a disease. We propose a Bayesian model that
addresses this question by incorporating information on pathways and gene
networks in the analysis of DNA microarray data. These information are used
to define pathway summaries, specify prior distributions, and structure the
MCMC moves to fit the model. We illustrate the method with an application
to gene expression data with censored survival outcomes. In addition to
identifying markers that would have been missed otherwise and improving
prediction accuracy, the integration of existing biological knowledge into the
analysis provides a better understanding of underlying molecular processes.
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2.1 Introduction
DNA microarrays have been used successfully to identify gene expression
signatures characteristic of disease subtypes Golub et al. (1999) or distinct
outcomes to therapy Shipp et al. (2002). Many statistical methods have
been developed to select genes for disease diagnosis, prognosis, and thera-
peutic targets. There is an increased consensus, however, that gene selection
alone may not be sufficient. In cancer pharmacogenomics, for instance, can-
cer drugs are increasingly designed to target specific pathways to account
for the complexity of the oncogenic process and the complex relationships
between genes Downward (2006). A pathway is generally defined as an or-
dered series of chemical reactions in a living cell, and it can be activated or
inhibited at multiple points. For example, if a gene at the top of a signaling
cascade is selected as a target, it is not guaranteed that the reaction will
be successfully inactivated because multiple genes downstream can still be
activated or inhibited. Even if a branch of the pathway is completely blocked
by inhibition or activation of multiple genes, the signal may still be relayed
through an alternative branch or even through a different pathway Bild et al.
(2006), Solit et al. (2006). Downward (2006) pointed out that targeting a
single pathway or a few signaling pathways might not be sufficient. Thus,
the focus is increasingly on identifying both relevant genes and pathways.
We propose a Bayesian model that addresses this question by incorporating
information on pathways and gene networks in the analysis of DNA microar-
ray data. These information are used to define pathway summaries, specify
prior distributions, and structure the MCMC moves to fit the model.
Several public and commercial databases have been developed to struc-
ture and store the vast amount of biological knowledge accumulated over
the years into functionally or biochemically related groups. These databases
focus on describing signaling, metabolic or regulatory pathways. Some ex-
amples include Gene Ontology (GO) The Gene Ontology Consortium (2000),
the Kyoto Encyclopedia of Genes and Genomes (KEGG) Ogata et al. (1999),
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MetaCyc Krieger et al. (2004), PathDB (www.ncgr.org/pathdb), Reactome
KnowledgeBase Joshi-Tope et al. (2005), Invitrogen iPath (www.invitrogen.com),
and Cell Signaling Technology (CST) Pathway (www.cellsignal.com). The
need to integrate gene expression data with the biological knowledge accu-
mulated in these databases is well recognized. Several software packages that
query pathway information and overlay DNA microarray data on pathways
have been developed. Nakao et al. (1999) implemented a visualization tool
that color-codes KEGG pathway diagrams to reflect changes in their gene
expression levels. GenMAPP Dahlquist et al. (2002) is another graphical
tool that allows visualization of microarray data in the context of biological
pathways or any other functional grouping of genes. Doniger et al. (2003)
have made use of GenMAPP to view genes involved in specific GO terms.
Another widely used method that relates pathways to a set of differentially
expressed genes is the gene set enrichment analysis (GSEA) Subramanian
et al. (2005). Given a list of genes ordered according to their correlation
with a phenotype, GSEA computes an enrichment score to reflect the degree
to which a pre-defined pathway is over-represented at the top or bottom of
the ranked list. These procedures are useful starting points to observe gene
expression changes in the context of known biological processes.
Some recent studies have gone a step further and have focused on incorpo-
rating pathway information or gene-gene network information into the analy-
sis of gene expression data. For example, Park et al. (2007) have attempted to
incorporate GO annotation to predict survival time, by first grouping genes
based on their GO membership, calculating the first principal component to
form a super-gene within each cluster then applying a Cox model with L1
penalty to identify super-genes, i.e., GO terms related to the outcome. Wei
& Li (2007) have considered a small set of 33 pre-selected signaling path-
ways and used the implied relationships among genes to infer differentially
expressed genes, and Wei & Li (2008) have extended this work by including
a temporal dimension. Li & Li (2008) and Pan et al. (2009) have proposed
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two different procedures that use the gene-gene network to build penalties in
a regression model framework for gene selection. Bayesian approaches have
also been developed. Li & Zhang (2009) have incorporated the dependence
structure of transcription factors in a regression model with gene expression
outcomes; in their approach a network is defined based on the Hamming dis-
tance between candidate motifs and used to specify a Markov random field
prior for the motif selection indicator. Telesca et al. (2008) have proposed a
model for the identification of differentially expressed genes that takes into
account the dependence structure among genes from available pathways while
allowing for correction in the gene network topology.
These methods use the gene-pathway relationships or gene network infor-
mation to identify either the important pathways or the genes. Our goal is to
develop a more comprehensive method that selects both pathways and genes
using a model that incorporates pathway-gene relationships and gene depen-
dence structures. In order to identify relevant genes and pathways, latent
binary vectors are introduced and updated using a two-stage Metropolis-
Hastings sampling scheme. The gene networks are used to define a Markov
random field prior on the gene selection indicators and to structure the
Markov chain Monte Carlo (MCMC) moves. In addition, the pathway infor-
mation is used to derive pathway expression measures that summarize the
group behavior of genes within pathways using the first latent components
obtained by applying partial least squares (PLS) regressions on the selected
genes from each pathway. We apply the model to simulated and real data
using the pathway structure from the KEGG database. The integration of
the pathway information allows the identification of relevant predictors that
would have been missed otherwise and also improves the prediction accuracy.
The paper is organized as follows. In Section 2, we discuss the model
formulation and prior specification. Section 3 describes the MCMC procedure
to fit the model and strategies for posterior inference. In Section 4, we
evaluate the performance of the method using simulated data and illustrate
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Figure 2.1: Directed acyclic graph for model – observables are represented
with squares and parameters with circles
an application of the method to gene expression data with survival outcomes.
We conclude with a brief discussion in Section 5.
2.2 Model Specification
In this Section, we describe how we incorporate pathway and gene network
information into a Bayesian modeling framework for gene and pathway selec-
tion. Figure 3.2 shows a graphical representation of the a priori dependence
structure among variables and parameters in the proposed model.
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2.2.1 Regression on Latent Measures of Pathway Ac-
tivity
Our goal is to build a model for identifying pathways related to a particular
phenotype while simultaneously locating genes from these selected pathways
that are involved in the biological process of interest. The data we have
available for analysis consist of:
1. Y , an n× 1 vector of outcomes.
2. X, an n×p matrix of gene expression levels. Without loss of generality,
X is centered so that its columns sum to 0.
3. S, a K × p matrix indicating membership of genes in pathways, with
elements skj = 1 if gene j belongs to pathway k, and skj = 0 otherwise.
4. R, a p×p matrix describing relationships between genes, with elements
rij = 1 if genes i and j have a direct link in the gene network, and
rij = 0 otherwise.
The matrices S and R are constructed using information retrieved from path-
way databases, see the application in Section 2.4.2 for details.
Since the goal of the analysis is to study the association between the re-
sponse variable and the pathways, we need to derive a score as a measure
of “pathway expression”, which summarizes the group behavior of included
genes within pathways. We do this by using the latent components from a
PLS regression of Y on selected subsets of genes from each pathway. A num-
ber of recent studies have, in fact, applied dimension reduction techniques to
capture the group behavior of multiple genes. Pittman et al. (2004), for in-
stance, first apply k-means clustering to identify subsets of potentially related
genes, then use as regressors the first principal components obtained from
applying principal component analysis (PCA) to each cluster. Bair et al.
(2006) start by removing genes that have low univariate correlation with the
outcome variable then apply PCA on the remaining genes to form clusters
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or conceptual pathways, which are used as regressors. Similarly, Carvalho
et al. (2008) use a factor model and interpret the factors as pathways. In
our method, instead of attempting to infer conceptual pathways, we use the
existing pathway information. We compute a pathway activity measure by
applying PLS regression of Y on a subset of selected genes from the path-
way. PLS has the advantage of taking into account the correlation between
covariates and the response variable Y , whereas PCA focuses solely on the
variability in the covariate data. The selection of a subset of gene expressions
to form the PLS components is similar in spirit to the sparse PCA method
proposed by Zou et al. (2006), which selects variables to be used to form the
principal components.
One approach for locating genes and pathways to be included in the
model consists of first deriving all possible first PLS components for pathway
k using each of the (2pk − 1) subsets of genes that can be formed from
the pk =
∑p
j=1 skj genes belonging to the pathway (the empty set is not
considered). Let Tk be the corresponding n× (2pk − 1) matrix of first latent
components. In order to identify the genes that contribute to the summary
measure of pathway k, a multinomial latent vector λk of size (2
pk − 1) is
introduced with λkl = 1 if column l of Tk is used as score for pathway k,
and λkl = 0 otherwise. In addition, a latent binary vector θ is introduced
for pathway selection. The linear regression model that relates the response
variable to the selected pathways and genes is then written as
Y = 1α +
Kθ∑
r=1
T r(λr)Br(λr) + ε, ε ∼ N (0, σ2I ), (2.1)
where Kθ =
∑K
k=1 θk is the number of selected pathways and where the
subscript (λr) identifies the first PLS latent component that corresponds to
the non-zero element of the multinomial vector λr and that is used as score
of pathway r, among the (2pr − 1) columns of T r; Br is the (2pr − 1)-vector
of regression coefficients associated with the matrix T r and Br(λr) is the non-
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zero element corresponding to the selected column T r(λr).
We introduce a simpler parametrization that is equivalent to model (2.1)
to ease the prior specification and the MCMC implementation. Instead of
defining K multinomial vectors of length (2pk − 1) to locate genes relevant
from each pathway, we use a single p×1 binary gene selection vector γ, where
γj = 1 if gene j is selected, and γj = 0 otherwise. The linear regression model
can then be defined as
Y = 1α +
Kθ∑
r=1
Tr(γ)βr(γ) + ε, ε ∼ N (0, σ2I ), (2.2)
where Tr(γ) corresponds to the first latent PLS component generated based
on the expression levels of selected genes belonging to pathway r, that is
using the Xj’s corresponding to srj = 1 and γj = 1. Note that, since in (2.1)
we only allow the selection of one column of T k as the score of pathway k,
the use of λk in (2.1) is equivalent to using γ coupled with the matrix S in
(2.2).
As we explain in Sections 2.2.3 and 2.2.4, the alternative parametrization
in (2.2) makes it easier to incorporate the gene network in the prior distribu-
tion for gene selection. In addition, the use of a p× 1 binary vector, instead
of K multinomial vectors of size (2pk − 1), simplifies the implementation of
an MCMC algorithm that explores the space of gene subsets and facilitates
the posterior inference for gene selection.
2.2.2 Models for Categorical or Censored Outcomes
In the construction above, we have assumed a continuous response. How-
ever, our model formulation can easily be extended to handle categorical or
censored outcome variables.
When Y is a categorical variable taking one ofG possible values, 0, . . . , G−
1, a probit model can be used Albert & Chib (1993), Sha et al. (2004),
Kwon et al. (2007). Briefly, each outcome Yi is associated with a vector
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(pi,0, . . . , pi,G−1), where pig = P (Yi = g) is the probability that subject i
falls in the g-th category. The probabilities pig can be related to the linear
predictors using a data augmentation approach. Let Zi be latent data corre-
sponding to the unobserved propensities of subject i to belong to one of the
classes. When the observed outcomes Yi correspond to nominal values, the
relationship between Yi and Zi = (zi,1, . . . , zi,G−1) is defined as
Yi =
{
0 if max1≤l≤G−1{zi,l} ≤ 0
g if max1≤l≤G−1{zi,l} > 0 and zi,l = max1≤r≤G−1{zi,l}
. (2.3)
A multivariate normal model can then be used to associate Zi to the predic-
tors
Zi = α1
T +
Kθ∑
r=1
Ti,r(γ)β r(γ) + εi, εi ∼ N (0,Σ), i = 1, . . . , n. (2.4)
If the observed outcomes Yi correspond, instead, to ordinal categories,
the latent variable Zi is defined such that
Yi = g if δg < Zi ≤ δg+1, g = 0, . . . , G− 1, (2.5)
where the boundaries δg are unknown and −∞ = δ0 < δ1 < . . . < δG−1 <
δG =∞. The latent variable Zi is then associated with the predictors through
the linear model
Zi = α +
Kθ∑
r=1
Ti,r(γ)βr(γ) + εi, εi ∼ N (0, σ2), i = 1, . . . , n. (2.6)
For censored survival outcomes, an accelerated failure time (AFT) model
can be used, Wei (1992), Sha et al. (2006). In this case, the observed data
are Yi = min(Ti, Ci) and δi = I{Yi ≤ Ci}, where Ti is the survival time for
subject i, Ci is the censoring time, and δi is a censoring indicator. A data
augmentation approach can be used and variables Zi can be introduced such
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that {
Zi = log(Yi) if δi = 1
Zi > log(Yi) if δi = 0
. (2.7)
The AFT model can then be written in terms of the latent Zi,
Zi = α +
Kθ∑
r=1
Ti,r(γ)βr(γ) + εi, (2.8)
where the εi’s are independent and identically distributed random variables
that may take one of several parametric forms. Sha et al. (2006) consider
cases where εi follows a normal or a t-distribution.
2.2.3 Prior for Regression Parameters
The regression coefficient βk in (2.2) measures the effect of the PLS latent
component summarizing the effect of pathway k on the response variable.
However, not all pathways are related to the phenotype and the goal is to
identify the predictive ones. Bayesian methods that use mixture priors for
variable selection have been thoroughly investigated in the literature, in par-
ticular for linear models, see George & McCulloch (1993, 1997) for multiple
regression, Brown et al. (1998b) for extensions to multivariate responses and
Sha et al. (2004) for probit models. A comprehensive review on special fea-
tures of the selection priors and on computational aspects of the method can
be found in Chipman et al. (2001). Similarly, here, we use the latent vector
θ to specify a scale mixture of a normal density and a point mass at zero for
the prior on each βk in model (2.2):
βk|θk, σ2 ∼ θk · N (β0, hσ2) + (1− θk) · δ0(βk), k = 1, . . . , K. (2.9)
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where δ0(βk) is a Dirac Delta function. For model (2.1), the prior specification
for the regression coefficients Bk requires conditioning on θk as well as λk,
Bkj|θk, λk, σ2 ∼ θk · [λkj · N (B0j, hσ2) + (1− λkj) · δ0(Bkj)]
+(1− θk) · δ0(Bkj)
(2.10)
for k = 1, . . . , K and j = 1, . . . , (2pk − 1). When conditioning on γ, the
posterior distributions of the selected regression coefficients induced by prior
(2.9) for model (2.2) and by prior (2.10) for model (2.1) are equivalent. It
is, however, easier to specify a prior that incorporates the gene dependence
structure for the p-vector γ than it is for the K multinomial vectors λk,
see Section 2.2.4 below. The hyperparameter h in (2.9) regulates, together
with the hyperparameters of p(θ, γ |η), the amount of shrinkage in the model.
We follow the guidelines provided by Sha et al. (2004) and specify h in the
range of variability of the data so as to control the ratio of prior to posterior
precision.
For the intercept term, α, and the variance, σ2, we take conjugate priors
α|σ2 ∼ N (α0, h0σ2) (2.11)
σ2 ∼ Inv-Gamma(ν0/2, ν0σ20/2),
where α0, β0, h0, h, ν0 and σ
2
0 are to be elicited.
2.2.4 Priors for Pathway and Gene Selection Indica-
tors
In this Section we define the prior distributions for the pathway selection
indicator, θ, and gene selection indicator, γ . These priors are first defined
marginally then jointly, taking into account some necessary constraints.
Each element of the latent K-vector θ is defined as
θk =
{
1 if pathway k is represented in the model
0 otherwise
(2.12)
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for k = 1, . . . , K. We assume independent Bernoulli priors for the θk’s,
p(θ|ϕk) =
K∏
k=1
ϕθkk (1− ϕk)1−θk , (2.13)
where ϕk determines the proportion of pathways expected a priori in the
model. A mixture prior can be further specified for ϕk to achieve a better
discrimination in terms of posterior probabilities between significant and non-
significant pathways by inflating p(θk = 0) toward 1 for the non-relevant
pathways, as suggested by Carvalho et al. (2008),
p(ϕk) = ρδ0(ϕk) + (1− ρ)B(ϕk|a0, b0), (2.14)
where B(ϕk|a0, b0) is a Beta density function with parameters a0 an b0. Since
inference on ϕk is not of interest, it can be integrated out to simplify the
MCMC implementation. This leads to the following marginal prior for θ
p(θ) =
∏
k
[
ρ · (1− θk) + (1− ρ) · B(a0 + θk, b0 + 1− θk)
B(a0, b0)
]
, (2.15)
where B(·, ·) is the Beta function. Prior (2.15) corresponds to a product of
Bernoulli distributions with parameter ϕ∗k =
a0(1−ρ)
a0+b0
.
For the latent p-vector γ , we specify a prior distribution that is able to
take into account not only the pathway membership of each gene but also
the biological relationships between genes within and across pathways, which
are captured by the matrix R. Following Wei & Li (2007), we model these
relations using a Markov random field (MRF), where genes are represented by
nodes and relations between genes by edges. A MRF is a graphical model in
which the distribution of a set of random variables follow Markov properties
that can be described by an undirected graph. In particular, a pair of genes
that are not connected are considered conditionally independent given all
other genes Besag (1974). Relations on the MRF are represented by the
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following probabilities
P (γj|η, γi, i ∈ Nj) = exp(γjF (γj))
1 + exp(F (γj))
, (2.16)
where F (γj) = µ + η
∑
i∈Nj(2γi − 1) and Nj is the set of direct neighbors
of gene j in the MRF using only pathways represented in the model, i.e.,
pathways with θk = 1. The parameter µ controls the sparsity of the model,
with higher values of η encouraging neighboring genes to take on the same
γj value. If a gene does not have any neighbor, its prior distribution reduces
to an independent Bernoulli with parameter p = exp(µ)/[1 + exp(µ)], which
is a logistic transformation of µ. The corresponding global distribution on
the MRF is given by
P (γ |θ, µ, η) ∝ exp(µ n1 − η n01), (2.17)
where n1 is the number of selected genes and n01 is the number of edges
linking genes with different values of γj (i.e., edges linking included and
non-included genes among all pathways),
n1 =
p∑
j=1
γj, n01 =
1
2
p∑
i=1
[
p∑
j=1
rij −
∣∣∣∣∣
p∑
j=1
rij(1− γi)−
p∑
j=1
rijγj
∣∣∣∣∣
]
.
In addition, we specify a Gamma hyperprior for η,
η ∼ Gamma(c0, d0). (2.18)
Constraints need to be imposed to ensure both interpretability and iden-
tifiability of the model. We essentially want to avoid the following scenarios:
1. creation of empty pathways, i.e., selecting a pathway but none of its
member genes;
2. creation of orphan genes, i.e., selecting a gene but none of the pathways
that contain it;
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3. selection of identical subsets of genes by different pathways, a situation
that generates identical values Tk(γ) and Tk′(γ) to be included in the
model.
These constraints imply that some combinations of θ and γ values are not
allowed. The joint prior probability for (θ, γ) taking into account these con-
straints is given by
pi(θ, γ |η) ∝
{ ∏K
k=1 ϕ
∗θk
k (1− ϕ∗k)1−θk exp(µn1 − ηn01) for valid comb.,
0 for invalid comb.
(2.19)
We note that specifying a prior of type (2.17) on the array λ = (λ1, . . . , λK)
from model (2.1) would in practice amount to reparameterizing the K multi-
nomial vectors into a p-binary vector, therefore bringing us back to model
(2.2). In addition, it is more straightforward to impose the constraints on
the p-binary vector γ than it is on the K multinomial vectors λk.
2.3 Model Fitting
We now describe the MCMC procedure to fit the model and discuss strategies
for posterior inference.
2.3.1 Marginal Posterior Probabilities
The model parameters consist of (α, β, σ2, γ, θ, η). The MCMC procedure
can be made more efficient by integrating out some of the parameters. Here,
we integrate out the regression parameters, α, β and σ2. This leads to a
multivariate t-distribution
f(Y |T , θ, γ) ∼ Tν0(α01n+T (θ,γ)β0, σ20(In+h01n1′n+T (θ,γ)Σ0T ′(θ,γ))), (2.20)
with ν0 degrees of freedom and 1n an n-vector of ones, and where Σ0 = hIKθ ,
with In the n× n identity matrix, and T(θ,γ) the n×Kθ matrix derived from
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the first PLS latent components for selected pathways using selected genes.
In the notation (2.20) the two arguments of the t-distribution represent the
mean and the scale parameter of the distribution, respectively. The posterior
probability distribution of the pathway and gene selection indicators is then
given by
f(θ, γ, η|T , Y ) ∝ f(Y |T , θ, γ) · pi(θ, γ |η) · pi(η). (2.21)
2.3.2 MCMC Sampling
The MCMC steps to fit the model consist of: (I) sampling the pathway
and gene selection indicators from p(θ, γ |rest); (II) sampling the MRF pa-
rameter from p(η|rest); (III) sampling additional parameters that would be
introduced when fitting a probit model for categorical outcomes or an AFT
model for survival outcomes.
(I) The parameters (θ, γ) are updated using a Metropolis-Hastings algo-
rithm in a two-stage sampling scheme. The pathway-gene relationships
are used to structure the moves and account for the constraints speci-
fied in Section 2.2.4. Figure 2.2 summarizes the transition moves in a
flow chart. Details of the MCMC moves for updating (θ, γ) are pro-
vided in the Appendix A. Briefly, they consist of randomly choosing
one of the following three move types:
1. change the inclusion status of gene and pathway by randomly
choosing between adding the score of a pathway and a gene (move
1.i in Figure 2.2) or removing them both (move 1.ii);
2. change the inclusion status of gene but not pathway by randomly
choosing between adding a gene (2.i) or removing a gene (2.ii);
3. change the inclusion status of pathway but not gene by randomly
choosing between adding a pathway (3.i) or removing a pathway
(3.ii).
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Figure 2.2: Proposed move types: (1.i) add a pathway and a gene (+,+);
(1.ii) remove a pathway and a gene (-,-); (2.i) add a gene in an existing
pathway (n,+); (2.ii) remove a gene from an existing pathway (n,-); (3.i) add
a pathway without touching genes (+,n); (3.ii) remove a pathway without
touching genes (-,n).
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(II) The MRF parameter η is sampled using a Metropolis-Hastings algo-
rithm, in which a candidate ηnew is generated from a truncated normal
distribution, with mean ηold and truncation at 0, which we denote by
q(ηold; ηnew). The variance of this distribution represents a tuning pa-
rameter chosen to allow a wide exploration of the parameter space and
to give a good acceptance rate. Alternatively, a Gamma density could
be used as proposal distribution. The acceptance probability is
min
{
f(γ|ηnew, θ)f(ηnew)q(ηold; ηnew)
f(γ|ηold, θ)f(ηold)q(ηnew; ηold) , 1
}
. (2.22)
(III) In the case of classification or survival outcomes, the augmented data
Z need to be updated from their full conditionals using Gibbs sampling
(see Sha et al. (2004, 2006), Kwon et al. (2007) for details on this step).
2.3.3 Posterior Inference
The MCMC procedure results in a list of visited models with included path-
ways indexed by θ and selected genes indexed by γ , and their correspond-
ing relative posterior probabilities. Pathway selection can be based on the
marginal posterior probabilities p(θk|T , Y ), estimated by the relative fre-
quency of inclusion of pathway k in the models visited by the MCMC sampler.
Relevant pathways can be identified as those with largest marginal posterior
probabilities. Then relevant genes from these pathways can be identified
based on their marginal posterior probabilities conditional on the inclusion
of a pathway of interest, p(γj|T , Y, I{θkskj = 1}). An alternative inference
for gene selection is to focus on a subset of pathways, P , and consider the
marginal posterior probability conditional on at least one pathway the gene
belongs to being represented in the model, p(γj|T , Y, I{
∑
k∈P θkskj > 0}).
Inference for a new set of observations, (X f , Yf ) can be done via least
squares prediction,
Ŷf = 1nα˜ + T f(θ,γ)β˜ (θ,γ), (2.23)
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where T f(θ,γ) is the first principal component based on selected genes from
relevant pathways and
α˜ = Y¯ , β˜ (θ,γ) = (T
′
(θ,γ)T (θ,γ) + h
−1IKθ)
−1T ′(θ,γ)Y,
with Y the response variable in the training and T (θ,γ) the scores obtained
from the training data using selected pathways and genes included in the
model. Note that for prediction purposes, since we do not know the future
Yf , a PLS regression cannot be fit. Therefore, we generate Tf(θ,γ) by consid-
ering the first latent component obtained by applying PCA to each selected
pathway using the included genes.
In the case of categorical or censored survival outcomes, the sampled
latent variables Z would be used to estimate Ẑf then the correspondence
between Z and the observed outcome outlined in Section 2.2.2 can be invoked
to predict Yf (Sha et al. (2004, 2006), Kwon et al. (2007)).
2.4 Application
We assess the performance of the model on simulated data then illustrate an
application to a breast cancer data using the KEGG pathway database to
define the MRF.
2.4.1 Simulation Studies
We investigated the performance of the model using simulated data based
on the gene-pathway relations, S, and gene network, R, of 70 pathways and
1098 genes from the KEGG database. The relevant pathways were defined
by selecting 4 pathways at random. For each of the 4 selected pathways,
one gene was picked at random and its direct neighbors that belong to the
selected pathways were chosen. This resulted in the selection of 4 pathways
and 15 genes: 7 out of 30 from the first pathway, 3 out of 35 from the second,
3 out of 105 from the third, and 2 out of 47 from the fourth pathway. Gene
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expressions for n = 100 samples were simulated for these 15 genes using an
approach similar to Li & Li (2008). This was accomplished by first creating
an ordering among the 15 selected genes by changing the undirected edges
in the gene networks into directed edges. The first node on the ordering,
which we denote by XF1 , was selected from each pathway and drawn from a
standard normal distribution; note that this node has no parents. Then all
child nodes directly connected only to XF1 and denoted by XF2 were drawn
from
XF2 ∼ N (XF1ρ, 1).
Subsequent child nodes at generation j, XFj , were drawn using all parents
from
XFj ∼ N (ρXpa(Fj)1|pa(Fj)|, 1)
whereXpa(Fj) is a matrix containing the expressions of all the |pa(Fj)| parents
for node j. The expression levels of the remaining 1073 genes deemed irrele-
vant were simulated from a standard normal density. The response variables
for the n = 100 samples were generated from
Yi =
15∑
j=1
Xijβ + εi, εi ∼ N (0, 1), i = 1, . . . , 100.
For the first dataset we set β = ±0.5, using the same sign for genes that
belong to the same pathway. For the second and third data sets we used
β = ±1 and β = ±1.5, respectively. Note that the generating process is
different from the model (2.2) being fit.
We report the results obtained by choosing, when possible, hyperparam-
eters that lead to weakly informative prior distributions. A vague prior is
assigned to the intercept parameter α by setting h0 to a large value tending
to∞. For σ2, the shape parameter can be set to ν0/2 = 3, the smallest inte-
ger such that the variance of the inverse-gamma distribution is defined, and
the scale parameter ν0σ
2
0/2 can be chosen to yield a weakly informative prior.
For the vector of regression coefficients, βk, we set the prior mean to β0 = 0
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Figure 2.3: Marginal posterior probabilities for pathway selection, p(θk|T , Y ),
for the three simulated data sets. The open circles indicate the four relevant
pathways.
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and h, as described in Section 2.2.3, is chosen in the range of variability of
the covariates. Specifically, we set h0 = 10
6, α0 = β0 = 0, ν0σ0/2 = 0.5, and
h = 0.02. For the pathway selection indicators, θk, we set ϕ
∗
k = 0.01. As
for the prior at the gene level, we set µ = −3, which corresponds to setting
the proportion of genes expected a priori in the model to around 5%, and
for the Gamma hyperprior on η we set c0 = 3.5 and d0 = 0.2 to obtain a
prior distribution with most of the mass between 0.1 and 2. This controls
the prior probability of selecting a gene based on how many of its neighbors
are selected, as defined in (2.16).
The MCMC sampler was run for 300,000 iterations with the first 50,000
used as burn-in. We computed the marginal posterior probabilities for path-
way selection, p(θk = 1|Y, T ), and the conditional posterior probabilities for
gene selection given a subset of selected pathways previously determined,
p(γj|Y, T , I{
∑
k∈P θkskj > 0}). Table 2.1 gives these posterior probabilities
for the relevant pathways and genes used in simulating the response. Figure
2.3 displays the marginal posterior probabilities of inclusion for all 70 path-
ways and Figure 2.4 displays the conditional posterior probabilities of inclu-
sion for all 1098 genes. The procedure successfully identified all significant
pathways and genes. All four relevant pathways were selected with marginal
posterior probabilities greater than 0.8. Reducing the selection threshold to
a marginal posterior probability of 0.5 pulls in two false positive pathways,
for all the three simulated scenarios considered. One of these is the pathway
indexed 17 in Figure 2.3, which contains more than 100 genes.
A closer investigation of the MCMC output reveals that different sub-
sets of its member genes are selected whenever it is included in the model,
resulting in a high marginal posterior of inclusion for the pathway but low
marginal posterior probabilities for all its member genes. The second false
positive pathway appears to be selected often because it contains two or three
of the relevant genes that were used to simulate the response variable and
were also included in the model with high marginal posterior probabilities; all
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Figure 2.4: Conditional posterior probabilities,
p(γj|T , Y, I{
∑
k∈P θkskj > 0}), for gene selection for the three simu-
lated data sets. The open circles indicate the genes used to generate the
outcome variable.
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Path/Gene β = ±0.5 β = ±1 β = ±1.5 Path/Gene β = ±0.5 β = ±1 β = ±1.5
Path1 0.967 0.992 0.983 Gene1.7 0.701 1.000 0.996
Path2 0.883 1.000 0.996 Gene2.1 0.981 1.000 0.976
Path3 0.996 1.000 1.000 Gene2.2 0.084 0.133 0.205
Path4 0.885 0.911 0.913 Gene2.3 0.156 0.246 0.380
Gene1.1 0.867 0.856 0.896 Gene3.1 0.688 0.771 0.765
Gene1.2 0.228 0.228 0.186 Gene3.2 0.340 0.373 0.190
Gene1.3 0.222 0.300 0.228 Gene3.3 0.831 0.967 0.996
Gene1.4 0.251 0.159 0.163 Gene4.1 0.463 0.675 0.682
Gene1.5 0.453 0.257 0.296 Gene4.2 0.990 0.993 0.974
Gene1.6 1.000 1.000 1.000
Table 2.1: Conditional and marginal posterior probabilities for pathway and
gene selections, p(γj = 1|T , Y, I{
∑
k∈P θkskj > 0}) and p(θk = 1|Y, T ).
its other member genes have very low probabilities of selection. As expected,
the identification of the relevant genes is easier when the signal-to-noise ratio
is higher. For the scenario with β = ±0.5, a marginal posterior probability
cut-off of 0.5 leads to the selection of 7 relevant genes and no false positive.
In order to select all 15 relevant genes, marginal posterior probabilities as
low as 0.084 need to be considered and this results in the inclusion of 14
false positives. For the simulated data with β = ±1, on the other hand, a
marginal posterior probability cut-off of 0.5 leads to the selection of 8 rele-
vant genes with no false positive, and reducing the cut-off to 0.132 results in
the inclusion of all 15 relevant genes with a single false positive.
2.4.2 Application to Microarray Data
We consider the van’t Veer et al. (2002) breast cancer microarray data,
available at www.rii.com/publications/2002/vantveer.htm. Gene expression
measures were collected on each patient using DNA microarray with 24,481
probes. Missing expression values were imputed using a k-nearest neighbor
algorithm with k = 10. The procedure consists of identifying the k closest
genes to the one with missing expression in array j using the other n− 1 ar-
rays, then imputing the missing value by the average expression level of the
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k neighbors, Troyanskaya et al. (2001). We focus on the 76 sporadic lymph-
node-negative patients, 33 of whom developed distant metastasis within 5
years and the remaining 43 did not; the latter are viewed as censored cases.
We randomly split the patients into a training set of 38 samples and a test
set of the same size. The goal is to identify a subset of pathways and genes
that can predict time to distant metastasis for breast cancer patients.
The gene network and pathway information were obtained from the KEGG
database. This was accomplished by mapping probes to pathways using
the links between pathway node identifiers and LocusLink ID provided at
ftp://ftp.genome.ad.jp/pub/kegg/pathways/hsa/hsa gene map.tab and
ftp://ftp.genome.ad.jp/pub/kegg/pathways/map title.tab.
Using the R package KEGGgraph Zhang & Wiemann (2009), we first
downloaded the gene network for each pathway then merged all the networks
into a single one with all the genes. A total of 196 pathways and 3,592
corresponding probes were included in the analysis. There is a many-to-
many correspondence between pathways and genes – each pathway contains
multiple genes and most genes are associated with several pathways.
We ran two MCMC chains with different starting numbers of included
variables, 50 and 80, respectively. We used 600,000 iterations with a burn-
in of 100,000 iterations. We incorporated the first latent vector of the PLS
for each pathway into the analysis as described in Section 2.2.1 and set the
number of pathways expected a priori in the model to 22. For the gene
selection, we set the hyperparameter of the Markov random field µ = −3.5;
this parameter regulates the sparsity of the model and indicates that a priori
at least 3% of genes are expected to be selected. As for η, the parameter
that regulates the smoothness of the distribution of γ over the graph and
influences the selection of neighboring genes, we set c0 = 3.5 and d0 = 0.2.
Sensitivity analysis with different choices of these hyperparameters showed
that the posterior inference is not affected for values of c0 between 2 and
4, and values of d0 between 0.15 and 2. For the prior of the regression
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Figure 2.5: Trace plot of the number of included pathways.
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Figure 2.6: Trace plot of the number of included genes.
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Figure 2.7: Scatterplot of p(θk|T , Y ) across the two MCMC chains.
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Figure 2.8: Microarray data: Marginal posterior probabilities for pathway
selection, p(θk|T , Y ). The 11 pathways with largest probabilities are marked
with symbols.
parameters, we set α0 = β0 = 0, h0 = 10
6 and h = 0.1. A vague prior was
specified for σ2 by choosing ν0/2 = 3 and ν0σ
2
0/2 = 0.5.
Figures 2.5 and 2.6 show the trace plots for the number of included path-
ways and the number of selected genes for one of the MCMC chains. The
MCMC samplers mostly visited models with 20-45 pathways and 50-90 genes.
To assess the agreement of the results between the two chains, we looked at
the correlation between the marginal posterior probabilities for pathway se-
lection, p(θk|T , Y ), and found good concordance between the two MCMC
chains with a correlation coefficient of 0.9996 (Figure 2.7).
The model also shows good predictive performance. Sha et al. (2006)
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Figure 2.9: Microarray data: Conditional posterior probabilities for gene
selection, p(γj|T , Y, I{
∑
k∈P θkskj > 0}). The 102 probes with largest proba-
bility that belong to the 11 selected pathways in Figure 2.8 are marked with
∆.
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already analyzed these data using an AFT model with 3,839 probes as pre-
dictors and selected 11 probe sets with highest marginal probabilities. They
obtained a predictive MSE(Zf , Zˆf ) of 1.9317 in the log scale. We applied
the method of Sha et al. to the 3,592 probe sets considered for analysis in
this paper. Using 4 chains with 600,000 iterations and 100,000 burn-in, we
selected a marginal model with 12 genes which resulted in a MSE(Zf , Zˆf ) of
2.6735. Our model incorporating pathway information achieved a predictive
MSE(Zf , Zˆf ) of 1.3955 using 11 selected pathways and 102 probe sets with
highest posterior probabilities. The selected pathways and genes are indi-
cated in the marginal posterior probability plots displayed in Figures 2.8 and
2.9. If we increase the marginal probability thresholds to select a comparable
number of probe sets as the method of Sha et al. (2006) and consider a model
with 7 selected pathways and 12 genes, we obtain a MSE(Zf , Zˆf ) of 1.5742.
The genes corresponding to the 102 selected probe sets are listed in Table
2.2 divided by islands, which correspond to sets of connected genes in the
Markov random field. The islands help with the biological interpretation by
locating relevant branches of pathways. A subset of the selected pathways
along with the islands and included genes that fall into them are displayed in
Figure 2.10. Several of the identified pathways are known to be involved in
tumor formation and progression. For instance, the mitogen-activated pro-
tein kinase (MAPK) signaling pathway, which is involved in various cellular
functions, including cell proliferation, differentiation and migration, has been
implicated in breast cancer metastasis Lee et al. (2007), Keyse (2008). The
KEGG pathway in cancers was also selected with high posterior probability.
Other interesting pathways are the insulin signaling pathway, which has been
linked to the development , progression, and outcome of breast cancer, and
purine metabolism which is involved in nucleotide biosynthesis and affects cell
cycle activity of tumor cells. In addition, several genes with known associa-
tion to breast cancer were also selected. For example, several dual specificity
phosphatase (DUSP) genes were selected from the MAPK signaling pathway,
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Figure 2.10: Microarray data: Graphical representation of a subset of se-
lected pathways and genes with their corresponding islands. The genes in
the islands are listed in Table 2.2.
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including DUSP3 found to map in a region that contains the BRCA1 locus
which confers susceptibility to breast and ovarian cancer Kamb et al. (1994).
Fibroblast growth factor 1 (FGF1) and protein kinase C alpha (PKCalpha),
which belong both to the MAPK pathway and the KEGG pathways in can-
cer, were also selected by the algorithm. The FGF family members have
broad mitogenic and cell survival activities, and are involved in a variety of
biological processes, including cell growth, tissue repair, tumor growth and
invasion, and in particular proliferation of breast cancer cells. PKCalpha
has been shown to be overexpressed in some antiestrogen resistant breast
cancer cell lines and to be involved in the growth of tamoxifen resistant hu-
man breast cancer cells Frankel et al. (2007). Other known genes that were
selected include Interleukin 8 (IL8) from the KEGG pathways in cancer, a
useful prognostic factor in metastatic breast cancer patients Ahmed et al.
(2006); ribosomal protein S6 kinase, 70kDa, polypeptide 1 (RPS6KB1) from
the insulin signaling pathway, which is overexpressed in some breast cancer
cell lines Kim et al. (2009); and DNA polymerase epsilon (POLE) from the
purine metabolism pathway, which is involved in DNA repair and has been
shown to be associated with breast cancer Zhou et al. (2008).
2.5 Discussion
We have proposed a model that incorporates biological knowledge from path-
way databases into the analysis of DNA microarrays to identify pathways and
genes related to a phenotype. Information on pathway membership and gene
networks are used to define pathway summaries, specify prior distributions
that account for the dependence structure between genes, and define the
MCMC moves to fit the model. The gene network prior and the synthesis of
the pathway information through PLS bring in additional information that
is especially useful in microarray data, where there is low sample size and
large measurement error. The performance of the method was evaluated us-
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Singleton genes (no direct neighbor selected)
ACACB(10), AGTR2(4), ARPC1B(9), BIRC5(11), C4A(8), CACNB4(2),
CCL13(3), CCNB2(5), CD22(7), CD28(7), CDC2(5), CFB(8), CFB(8), CR2(8),
CTNNA1(11), CXCL9(3), DIAPH3(9), DOCK1(9), EPHA8(6), EPHB1(6),
FBP1(10), FGF1(2, 9, 11), GMPS(1), GYS1(10), GYS2(10), IFNA7(3), IL8(3,
11), ITGA7(9), MAP4K2(2), ORC2L(5), P2RX7(4), PCK1(10), PCK2(10),
PCNA(5), PFKL(10), PFKM(10), PFKP(10), PFN1(9), POLD2(1), POLD3(1),
POLD4(1), POLE(1), PPARGC1A(10), PRKAR1A(10), RALBP1(11),
SELP(7), SHC1(10), SHC1(10), SHC2(10), SLC2A1(11), SORBS1(10),
TGFA(11), TMSB4Y(9)
Island 1
ACVR1B(2, 3, 11), ACVR1B(2, 3, 11), TGFB3(2, 3, 5, 11)
Island 2
BUB1(5), MAD2L1(5)
Island 3
C8B(8)8, C9(8)
Island 4
CALM3(10), NOS1(11)
Island 5
CD4(7), HLA-DMA(7), HLA-DMB(7), HLA-DOA(7), HLA-DOB(7), HLA-
DPA1(7), HLA-DPB1(7), HLA-DQB1(7), HLA-DRA(7), HLA-DRB1(7), HLA-
DRB3(7), HLA-DRB4(7), HLA-DRB5(7)
Island 6
CD8A(7), HLA-A(7), HLA-B(7), HLA-B(7), HLA-E(7)
HLA-F(7), HLA-G(7)
Island 7
CLDN11(7), OCLN(7)
Island 8
DUSP3(2), DUSP4(2), MAPK10(2, 10, 11)
Island 9
DVL3(11), FZD9(11), WNT1(11), WNT2B(11)
Island 10
PDPK1(10), PRKCI(10), RPS6KB1(10)
Island 11
F11R(7), GNAI1(6), PLA2G4A(2), PRKCA(2, 11), PRKX(2, 10), PRKY(2,
10), PRKY(2, 10), PTGS2(11)
Table 2.2: Selected 102 genes divided by islands with associated path-
way indices (in parenthesis). The pathway indices correspond to: 1-Purine
metabolism, 2-MAPK signaling pathway, 3-Cytokine-cytokine receptor inter-
action, 4-Neuroactive ligand-receptor interaction, 5-Cell cycle, 6-Axon guid-
ance, 7-Cell adhesion molecules (CAMs), 8-Complement and coagulation
cascades, 9-Regulation of actin cytoskeleton, 10-Insulin signaling pathway,
11-Pathways in cancer. The threshold for pathway inclusion was set to a
marginal posterior probability of 0.45.
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ing simulated data, and a breast cancer gene expression data with survival
outcomes was used to illustrate its application. The model can lead to the
selection of significant genes that would have been missed otherwise, and, as
shown in Section 2.4.2, it can achieve better prediction results compared to
models that do not treat genes as connected elements that work in groups or
pathways.
Several MRF priors for gene selection indicators have been proposed in
the literature. It is interesting to compare the parametrization of the MRF
used in this paper and in Wei & Li (2007) to the parametrization used in Li
& Zhang (2009), where the prior on γ is defined as
P (γ) ∝ exp(d′γ + γ ′Gγ) (2.24)
with d = d1p, 1p the unit vector of dimension p and G a matrix with elements
{gij} usually set to some constants. While d plays the same role as µ in (2.17),
the parametrization using G has a different effect from η on the probability
of selection of a gene. This is evident from the conditional probability
P (γj|γi, i ∈ Nj) =
exp(γj(d+ g
∑
i∈Nj γi))
1 + exp(d+ g
∑
i∈Nj γi)
, (2.25)
which can only increase as a function of the number of selected neighbor
genes. In contrast, with the parametrization in (2.17), the prior probability
of selection for a gene can decrease if none of the neighbors are selected.
Although the parametrization is somewhat arbitrary, some care is needed in
deciding whether to put a prior distribution on G. Allowing G to vary can
lead to a phase transition problem, that is, the dimension of the selected
model can increase massively. To avoid such problem, the parametrization
used in Li & Zhang (2009) requires fixing the hyperparameter G, which
could lead to the specification of a prior distribution that overwhelms the
likelihood function. In the parametrization (2.17), however, η is sampled
from its posterior distribution, and thus the influence of the gene network
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prior will be mitigated.
Pathway databases are incomplete and the gene network information is
often unavailable for many genes. Thus, there may be situations where the
dependence structure and the MRF prior specification on the gene selection
indicator, γ, cannot be used for all genes. When the only information avail-
able is the pathway membership of genes, the prior on γ could be elicited so
as to capture other interesting characteristics. For example, we may want
a gene to have a priori higher probability of being selected when several
pathways that contain it are included in the model. We may also want to
avoid favoring the selection of a large pathway just because of its size. In
such cases, conditional on θ, independent Bernoulli priors can be specified
for γj by relating the probability of selection to the proportion of included
pathways that contain gene j and adjusting for the pathway sizes, pk, that
is,
γj|θ ∼ Bernoulli
(
c ·
∑K
k=1 θkskj/pk∑K
k=1 skj/pk
)
, (2.26)
where the scalar c is a hyperparameter to be elicited. Notice that in this
case it may be be difficult to specify an equivalent prior for the multinomial
vectors λk in model (2.1) because of the overlapping genes among pathways.
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Chapter 3
Bayesian Network for Genomic
Data Integration
It has been estimated that about 30% of the genes in the human genome are
regulated by microRNAs (miRNAs). These are small RNAs that can down-
regulate the levels of mRNAs or proteins in animals and plants. Genes regu-
lated by miRNAs are called targets. Typically, methods for target prediction
are based solely on sequence data and on the structure information. In this
paper, we propose a Bayesian graphical modeling approach that infers the
miRNA regulatory network by integrating expression levels of miRNAs with
their potential mRNA targets and, via the prior probability model, with their
sequence/structure information. We use a directed graphical model with a
particular structure adapted to our data based on biological considerations.
We then achieve network inference using stochastic search methods for vari-
able selection that allow us to explore the huge model space via MCMC.
A time-dependent coefficients model is also implemented. We consider ex-
perimental data from a study on a very well known developmental toxicant
causing neural tube defects, hyperthermia. Some of the pairs of target gene
and miRNA we identify seem very plausible and warrant future investigation.
Our proposed method is general and can be easily applied to other types of
network inference by integrating multiple data sources.
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3.1 Introduction
One of the major tasks and challenges in the post-genomics era is to de-
cipher how genes and their products (proteins) are regulated. Regulation
can happen at transcriptional, post-transcriptional, translational and post-
translational level. Transcription is the process of synthesizing a stretch of
ribonucleic acids (RNA) based on a specific DNA sequence. Transcriptional
regulation can affect whether or not a specific RNA is transcribed as well as
the amount of RNA produced. RNA can be regulated post-transcriptionally
through degradation or modification of the RNA strand, which can affect its
function. A segment of RNA can interact with other genes or proteins or can
encode a protein. Translation, the process of forming a protein based on an
RNA sequence, can also be positively or negatively regulated. Proteins often
undergo post-translational modifications, which can affect their function. An
abundant class of small (∼22 nucleotide) RNAs, known as microRNAs (miR-
NAs), plays crucial regulatory roles in animals and plants, Farh et al. (2005).
It has been estimated that at least 30% of the genes in human genomes are
regulated by miRNAs, Rajewsky (2006). Genes regulated by miRNAs are
generally called ’targets’. The actual mechanism of miRNA regulation is still
an active area of research and the complete picture of the regulatory mech-
anism is still to be understood, Thermann & Hentze (2007). Currently, it is
believed that miRNAs regulate their targets either by degrading mRNA post-
transcriptionally, Bagga et al. (2005), or by suppressing initiation of protein
synthesis, Pillai et al. (2005), and/or by inhibiting translation elongation
after initiation of protein synthesis, Petersen et al. (2006).
Many algorithms have been developed to predict potential target se-
quences for miRNAs based on their specific sequence and structure char-
acteristics. These algorithms mainly use sequence information, hybridiza-
tion energy for structure prediction, and cross-species comparisons, Rajew-
sky (2006). Some of the more widely used algorithms include: TargetScanS
of Lewis et al. (2005), PicTar of Krek et al. (2005), MIRANDA of John et al.
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(2004) and DIANA-microT of Kiriakidou et al. (2004). A comprehensive
review of these and other methods can be found in Yoon Yoon & Micheli
(2006). Typically a large amount (e.g., hundreds to thousands) of poten-
tial targets are predicted by these algorithms, and it can be overwhelming
for researchers to search through the candidate targets for those which play
critical regulatory roles under particular experimental or clinical conditions.
Our goal is to develop a statistical approach to identify a small set of
potential targets with high confidence, making future experimental valida-
tion feasible. Since miRNAs down-regulate the expression of their targets,
expression profile of miRNAs and their potential targets can be used to in-
fer their regulatory relationships. We propose a Bayesian graphical modeling
approach that infers the miRNA regulatory network by integrating these two
types of expression levels. We use a directed graphical model with a partic-
ular structure adapted to our data based on biological considerations. The
model also integrates the sequence/structure information, as generated by
the two widely used target prediction algorithms, via the prior probability
model. We then achieve network inference using stochastic search methods
for variable selection.
We consider experimental data from a study on a very well known de-
velopmental toxicant causing neural tube defects, hyperthermia. We have
available 23 mouse miRNAs and a total of 1,573 potential targets. We in-
fer their regulatory network under two different treatment conditions and
also investigate time-dependent regulatory associations. Some of the pairs of
target gene and miRNA we identify seem very plausible and warrant future
investigation.
Huang et al. (2007, 2008) have proposed a Bayesian model for the regu-
latory process of targets and miRNAs which is similar to the one we propose
here. However, in their model formulation the authors consider regression
coefficients that are constant with respect to the mRNAs, while our formu-
lation allows a more efficient way of selecting gene-miRNA pairs. Also, in
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order to achieve posterior inference, we implement a full MCMC procedure
while Huang et al. (2007) adopt a variational method that only approximates
the posterior distribution. More important, Huang et al. (2007) restrict their
search algorithm to a preselected subset of possible gene-miRNA relations,
which they select based on the available sequence information, therefore ex-
cluding a priori a large number of associations that could instead occur in
specific experimental conditions, such as hyperthermia.
The paper is organized as follows. Section 3.2 introduces the experimental
study and describes the available data, i.e., the expression data of miRNAs
and their potential mRNA targets, and the corresponding association scores.
Section 3.3 illustrates the proposed modeling approach via a Bayesian graph-
ical model and describes the prior model and the variable selection scheme.
Section 3.4 describes how to perform posterior inference and Section 3.5 pro-
vides a detailed analysis of the miRNA regulatory network reconstruction
based on the available data. Section 3.6 concludes the paper.
3.2 Neural Tube Defects
Neural Tube defects (NTDs) are some of the most common congenital defects
with approximately 12 per day in the United States, Finnell et al. (2000).
NTDs are generally related to failure of embryonic neural folds to fuse prop-
erly along the neuroaxis during development. Studies in both humans and
animals suggest a complex genetic component to NTDs, likely involving mul-
tiple loci, together with environmental factors. MicroRNAs are believed to
play important regulatory roles in mouse development and human disease,
see for example Conrad et al. (2006), although detailed regulatory mecha-
nisms are still unknown.
In this paper we consider experimental data from a study on a very well
known developmental toxicant causing neural tube defects, hyperthermia. In
the study mice are used as the animal model to study NTDs. Time-mated
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female C57Bl/6 mice were exposed in vivo to a 10 minute hyperthermia or
control treatment on gestational day 8.5, when the neural folds are fusing
to form the neural tube. Four litters were collected for each treatment at
5, 10, and 24 hours after exposure. Each litter was treated as a single bio-
logical sample. MiRNAs and mRNAs were extracted from each sample for
expression analysis.
3.2.1 miRNA Expression Levels
As the regulatory network can be very complex, we focus on a small sets of
mRNA targets with high confidence. With limited budget available, a pilot
study was performed to screen the expression profiles of most of the known
(∼ 240) mouse microRNAs based on one set of samples, for both heat shock
and control at 4 different time points, and using TaqMan miRNA RTPCR
assays available at the time (Applied Biosystems, Foster City, CA; provided
in collaboration with Ambion, Austin, TX). Of the 240 miRNA evaluated,
50 had none or very low expression at all time points, while 86 had a 2-
fold or greater change in expression in response to hyperthermia exposure at
one or more time point. From this set of 86 miRNA, we chose a subset of
23 miRNA whose patterns of expression were interesting enough for further
analysis and obtained replicate sample sets. The complete experiment was
therefore carried out using only this set of 23 miRNAs.
MicroRNA was extracted from each sample at each time point under
each experimental condition. Two technical replicates were prepared for
RTPCR quantification to confirm the technical reproducibility. In RTPCR
experiments, fluorescence techniques are used to detect the amplification of
miRNAs to assess their abundance. A fluorescence threshold is determined
for an experiment, and the cycle number, which reaches the predetermined
threshold level of log2-based fluorescence, is defined as the Ct number. An
inverse linear relationship exists between Ct number and the logarithm of
input quantity of the gene when the amplification efficiency is perfect, Pfaffl
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(2001). The Ct numbers of the miRNA technical replicates were averaged
across the two technical replicates.
3.2.2 Target Prediction via Sequence and Structure
Information
The sequence and structure information for target prediction was retrieved
from the public domain by using the widely used algorithm PicTar of Krek
et al. (2005)1. A zero or absent PicTar score indicates that the raw score did
not exceed a pre-specified threshold, that is, the algorithm suggests no indi-
cation of a regulatory association. A matlab script was written to retrieve
the RefSeq Ids of all potential targets for the 23 mouse miRNAs of interest.
In addition, the current release (September 2009) of 1,209,841 predicted mi-
croRNA target sites in 26,697 mouse gene isoforms for 491 mouse miRNAs,
generated by the Miranda algorithm of John et al. (2004) was downloaded
from microRNA.org, see Betel et al. (2008). A matlab script was written
to retrieve the scores between the 23 miRNAs in our study and putative
target genes for the analysis.
3.2.3 Target mRNA Expression Levels
RNA was extracted from each sample at each time point and hybridized
to GE Codelink Mouse Whole Genome Microarrays(GE Healthcare Life Sci-
ences, Piscataway, NJ). The slides were scanned and mRNA expression levels
were quantified. One biological sample was not prepared properly at hour 10
in the control group, and therefore discarded.
The RefSeq Ids of the probes spotted on the Codelink microarrays were
linked to the retrieved potential targets of the 23 miRNAs previously iden-
tified. The mRNAs were included in the analysis only if they were among
the potential targets predicted by the PicTar and Miranda algorithms. Genes
1available at http://pictar.bio.nyu.edu/cgi-bin/new PicTar mouse.cgi
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with missing or negative values were excluded from the analysis. The expres-
sion levels of the remaining mRNAs were then log2 transformed so that both
miRNA and mRNA expression were on the log2 scale. A total of 1,573 poten-
tial targets was included in the final analysis. The transformed expressions
across the 3 time points were centered by subtracting their means.
3.3 Model
We have available expression levels on a set of miRNAs and their potential
targets. For each target we are interested in identifying a small number of
regulatory associations with high confidence. We have also available sequence
information for target prediction in the form of scores of regulatory associ-
ations. We propose a Bayesian graphical modeling approach that infers the
miRNA regulatory network by integrating the expression data and, via the
prior probability model, the sequence/structure information. An important
aspect of our methodology is the concept of sparsity, that is, we believe that
most genes are regulated by a small number of miRNAs.
3.3.1 A Bayesian Network for Gene & miRNA Expres-
sion
We use a directed graphical model (Bayesian Network) with a particular
structure adapted to our data that uses a predetermined ordering of the
nodes based on biological considerations. This model is able to answer to
the baseline question of ’which miRNAs regulate which targets ’ and, in ad-
dition, allows us to build a fast computational procedure required in such a
high-dimensional framework. A graphical representation of the full miRNA
network is given in Figure 3.1. Our task is to find a significant subset of
edges.
Graphical models are graphs in which nodes represent random variables
and the lack of arcs represents conditional independence assumptions, see
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Figure 3.1: Graphical representation of the miRNA regulatory network.
for example Cowell et al. (1999). Graphical models provide a compact rep-
resentation of joint probability distributions. Here we work with a multi-
variate normal distribution, and therefore with a Graphical Gaussian model
(GGM). A graph G and the covariance matrix Ω entirely define a GGM M,
M≡ (G,Ω). Arcs can be undirected, indicating symmetric dependencies, or
directed, when there is a direction of the dependence. These dependencies
can come from prior knowledge or from data analysis. Undirected graphical
models have a simple definition of independence, e.g., two nodes A and B are
conditionally independent given a third set, C, if all paths between the nodes
in A and B are separated by a node in C. Directed graphical models need a
specific ordering of the variables. Graphs that do not allow the presence of
cycles are called directed acyclic graph (DAG). Conditional independencies
in a DAG depend on the ordering of the variables.
We work with a DAG and impose an ordering of the variables such that
each target can be affected only by the miRNAs and that the miRNAs can
affect only the targets. Let Z = (Y1,Y2, . . . ,YG,X1, . . . ,XM) with Y =
(Y1, . . . ,YG) the matrix representing the targets and X = (X1, . . . ,XM)
the miRNAs . Specifically, yng indicates the normalized averaged log2 gene
expression of gene g = 1, . . . , G in sample n = 1, . . . , N . These expression
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values are biological replicates obtained by averaging two technical replicates.
Similarly, xnm indicates the expression of the m-th miRNA in sample n,
with m = 1, . . . ,M . We have G = 1, 573 and M = 23. In addition, we
have N = 11 i.i.d. observations under the control status and N = 12 i.i.d.
observations under hyperthermia. We infer the miRNA regulatory network
separately under the two conditions.
Our assumptions are that Z is a matrix-variate normal variable with zero
mean and a variance matrix Ω for its generic row, that is, following Dawid
(1981) notation,
Z− 0 ∼ N (IN ,Ω).
In addition, we assume that the target genes are independent conditionally
upon the miRNAs, that is, Yi⊥⊥Yj|X1, . . . ,XM and, without loss of gen-
erality, that the miRNAs are independent, that is, Xi⊥⊥Xj. Note that the
marginal distribution of (X1, . . . ,XM) does not affect the regulatory network.
In a Bayesian Network framework these assumptions imply an ordering of
the nodes and, consequently, a likelihood factorization of the type:
f(Z) =
G∏
g=1
f(Yg|X)
M∏
m=1
f(Xm), (3.1)
where f(Yg|X) ∼ N(Xβg, σgIN) and f(Xm) ∼ N(0, σmIN), with βg =
Ω−1XXΩXYg and σg = ωgg − ΩTXYgΩ−1XXΩXYg . Here ωgg indicates the g-th
diagonal element of Ω and ΩXX, ΩXY are the blocks of the covariance matrix
according to the following partition
Ω =
(
ΩYY ΩYX
ΩXY ΩXX
)
.
For m = 1, . . . ,M we have σm = ωmm.
According to current knowledge, miRNAs down-regulate gene exppres-
sion. It therefore seems appropriate to include this information into our
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Figure 3.2: Structure of the graphical model
statistical model. This is achieved by specifying negative regression coeffi-
cients, i.e. by imposing the constraints βg > 0, for g = 1, . . . , G, via the prior
model. First, we note that our model is equivalent to the following system
of equations: 
Y1 = −Xβ1 + ²σ1 ,
...
YG = −XβG + ²σG ,
(3.2)
where ²σg is distributed as a multivariate normal with zero mean and covari-
ance matrix σgIN . Then, we complete the model specification by specifying
prior distributions on the regressions coefficients and error variances. We
impose our biological constraints by using Gamma distribution priors for the
positive regressions coefficients, (βgm|σg) ∼ Ga(1, c σg), and Inverse-Gamma
distributions for error variances, σ−1g ∼ Ga((δ+M)/2, c/2). Figure 3.2 shows
a graphical representation of our model. Circles indicate parameters and
squares observed random variables. The parameters R and τ are involved in
the variable selection and are introduced in the Section below.
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3.3.2 Prior Model for Variable Selection
The goal of the analysis is to find, for each target, a small subset of miRNAs
that regulate that target with high probability. This can be framed into a
variable selection problem. Specifically, we can introduce a (G×M) matrix
R with elements rgm = 1 if the mth miRNA is included in the regression of
the gth target and rgm = 0 otherwise. Conditioned upon R expression (3.2)
is equivalent to a system of linear equations where the included regressors
are only those miRNAs corresponding to rgm = 1. To emphasize the variable
selection nature of our model we write it as follows:
Yg = −X(R)βg(R) + ²σg , (3.3)
where βg(R) is the vector that is formed by taking only the non-zero elements
of βg and X(R) is the matrix that is formed by taking only the corresponding
columns of X. The goal of our modeling is to infer which elements of the
vectors βg’s are non-zero, indicating a relationship between the corresponding
genes and miRNAs. This underlying regulatory network is encoded by the
association matrix R = {rgm}. The elements of the vectors βg’s are then
stochastically independent, given the regulatory network R, and have the
following mixture prior distribution:
pi(βgm|σg, rgm) = rgmN(0, c−1σg) + (1− rgm)I[βgm=0]. (3.4)
In addition, taking into account the regulatory network, we obtain that
σ−1g |R ∼ Ga((δ+kg)/2, c/2), where kg is the number of significative miRNAs
in the regression of the g-th target.
Mixture priors have been used extensively for variable selection in linear
regression settings, see George & McCulloch (1993) for univariate regression
and Brown et al. (1998b) and Sha et al. (2004) for multivariate models.
According to prior (3.4), when rgm = 0 then βgm is estimated by 0 and
the corresponding column of X is excluded from the gth equation in model
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(3.2). Notice that the dimensions of the matrix X are such that there are
many more columns than rows. In the domain of classical regression, this
results in insufficient degrees of freedom to fit the model unless constraints are
placed on the regression coefficients βg’s. Conversely, this problem is readily
addressed in the Bayesian paradigm and is known as the “small n, large p”
framework. The variable selection formulation we adopt here overcomes the
somehow rigid structure of the model in Brown et al. (1998b), which does not
allow to select different predictors for different responses. See also Monni &
Tadesse (2009) for an approach based on partition models.
3.3.3 Using Association Scores in the Prior Model
Scores of possible associations between gene-miRNA pairs obtained from
sequence/structure information were used to estimate prior probabilities of
miRNAs binding to their target genes. Let sgm denote a generic score for
gene g and miRNA m, obtained for example by the PicTar algorithm. As
previously described, sgm is either positive or, in the case of a regulatory
association that is believed to be absent, equal to zero. Also, the PicTar
algorithm shrinks small values to zero, setting sgm = 0 if sgm < ε where ε is
a pre-specified threshold used by the algorithm. In our model, the Bernoulli
random variable rgm indicates whether there is a relationship between gene
g and miRNA m. We choose to model the success probability of rgm as a
function of the sgm score as follows:
P (rgm = 1|τ) = exp[η + τsgm]
1 + exp[η + τsgm]
, (3.5)
where τ is an unknown parameter. We then assume that the elements of
R are stochastically independent given τ . Notice that for sgm = 0, we have
that P (rgm = 1) = exp[η]/(1 + exp[η]). Thus, the inverse logit transforma-
tion of η can be interpreted as the false negative rate associated with the
PicTar thresholding scheme. For a score sgm > 0 we have P (rgm = 1) > η,
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with higher scores yield higher prior probabilities of association. We further
specify a hyperprior on τ as a gamma distribution τ ∼ Ga(aτ , bτ ), ensuring
the positivity of the parameter.
Since we have available multiple prior sources of information, from dif-
ferent sequence/structure algorithms, it makes sense to combine them all by
incorporating all scores into the prior distribution using additional τ param-
eters. For example, in the application of Section 5 we combine PicTar and
Miranda scores as
P (rgm = 1|τ1, τ2) = exp[η + τ1sgm + τ2qgm]
1 + exp[η + τ1sgm + τ2qgm]
, (3.6)
where the qgm’s denote the Miranda scores.
3.3.4 Time-dependent Coefficients Model
The previous model implies that the relation between gene g and miRNA m
is constant over time. In the experimental study for which we developed our
model there is no dependence between the measurements at different time
points, since these observations come from independent units. However, one
may still wish to incorporate into the model the fact that relations may
possibly change with time. This can be done by allowing different regression
coefficients at different time points, as follows:
Y1 = −Xβ1 −X∗2β′1 −X∗3β′′1 + ²σ1 ,
...
YG = −XβG −X∗2β′G −X∗3β′′G + ²σG ,
(3.7)
where the Yg’s are N × 1 vectors and
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X =
 X1X2
X3
 , X∗2 =
 0X2
0
 , X∗3 =
 00
X3
 ,
are the N ×M matrices of the observed values, with X1, X2 and X3 the
miRNA expressions collected at the first, the second and the third time point,
respectively. The element βgm ∈ βg represents the relation between gene g
and miRNA m at the first time point, βgm + β
′
gm, with β
′
gm ∈ β′g, represents
the relation at the second time point and βgm + β
′′
gm, with β
′′
gm ∈ β′′g , at the
third time point.
In order to do variable selection on the elements of β′g and β
′′
g we intro-
duce two additional binary matrices R′ and R′′, with a similar role to R
in the time-invariant model (3.3). We consider the elements of R′ and R′′
independently distributed and following a Bernoulli distribution with param-
eter P (r′gm = 1) = ηb = P (r
′′
gm = 1). Because of the way we implement the
MCMC, see Section 3.4, we do not need to impose the sequence information
on the prior on R′ and R′′.
As for the elements of the βg’s vectors, we assume that the elements of
the β′g’s and β
′′
g ’s vectors are stochastically independent given the regulatory
networks R′ and R′′, respectively, and that they have the following prior
distributions:
pi(β′gm|σg, r′gm) = r′gmN(0, c−1σgζ) + (1− r′gm)I[β′gm=0],
pi(β′′gm|σg, r′′gm) = r′′gmN(0, c−1σgζ) + (1− r′′gm)I[β′′gm=0],
where the hyperparameter ζ, usually ≤ 1, reflects the prior information on
the magnitude of the β′g’s and β
′′
g ’s.
We can reframe the time-dependent coefficients model in the same way
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we have framed model (3.3), that is:
Yg = −X(R)βg(R) −X∗2(R′)β′g(R′) −X∗3(R′′)β′′g(R′′) + ²σg ,
where the columns of X∗2 are selected if the corresponding elements of R
′ are
equal to 1 and the columns of X∗3 are selected if the corresponding elements
of R′′ are equal to 1, for each equation.
3.4 Posterior Inference
For posterior inference the primary interest is in estimating the association
matrix R. Here we show that R can be estimated by designing a simple
extension of the stochastic search procedures used for variable selection, see
George & McCulloch (1993) and Sha et al. (2004), among many others.
We use a Metropolis-Hastings within Gibbs to explore the huge model
space and find the most influential predictors. Our model has 23 regressors
for each of 1,573 equations, that is a total of 36, 179 regression coefficients
for the time invariant model (3.3) and 108, 537 for the time dependent model
(3.7). Clearly, exploring such a huge posterior space is challenging. Here we
exploit the sparsity of our model, i.e., the belief that most of the genes are
well predicted by a small number of regressors, and resort to a Stochastic
Search Variable Selection (SSVS) method. A stochastic search allows us
to explore the posterior space in an effective way, quickly finding the most
probable configurations, i.e., those corresponding to the coefficients that have
high marginal probability of rgm = 1, while spending less time in regions with
low posterior probability.
In order to design this MCMC search we need to calculate the marginal
posterior distribution of R by integrating out βg from the posterior:
f(Yg|X(R), σg,R) ∝ 1
(2pi)(N−kg)/2σN/2g ckg
|Ug|1/2
exp[ 1
2σg
qg]Φkg(0;−UgCg, σgUg),
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where Ug = (X
T
(R)X(R))
−1, Cg = YTgX
T
(R) − (σ1/2g /c)1kg and qg = YTgYg −
CgUgC
T
g and with kg the number of selected regressors. Φkg(0;−UgCg, σgUg)
indicates the cdf of a multivariate normal, with mean −UgCg and covariance
matrix σgUg, calculated at the zero vector.
Our algorithm consists of three steps. The first step is based on the
marginal posterior distribution conditioned upon τ1, τ2, σg and consists of
either the addition or the deletion of one arrows in our graphical model or
the swapping of two arrows. The second step generates new values of τ1
and τ2 from their posterior distribution. In the last step values of all the
error variances σg are updated. The un-normalized full conditionals needed
for the Gibbs sampler can be derived from the conditional independencies of
our model, as given in Figure 3.2. We now describe the three steps of the
algorithm:
1. We use one of two types of moves to update R:
• with probability φ, we add or delete an element by choosing at
random one component in the current R and changing its value;
• with probability 1−φ, we swap two elements by choosing indepen-
dently at random one 0 and one 1 in the current R and changing
the value of both of them.
The proposed Rnew is then accepted with a probability that is the
ratio of the relative posterior probabilities of the new versus the current
model:
min
[
f(Y|X(Rnew),Rnew, σg)pi(Rnew|τ)
f(Y|X(Rold),Rold, σg)pi(Rold|τ)
, 1
]
. (3.8)
Because these moves are symmetric, the proposal distribution does not
appear in the previous ratio.
2. In order to update τ1 and τ2 we employ another two Metropolis steps.
The proposal is made via a truncated normal random walk kernel. The
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proposed τnew1 is then accepted with probability:
min
[
pi(R|τnew1 )pi(τnew1 )q(τ old1 ; τnew1 )
pi(R|τ old1 )pi(τ old1 )q(τnew1 ; τ old1 )
, 1
]
, (3.9)
where q(τ old1 ; τ
new
1 ) is a truncated normal with mean τ
new
1 and trunca-
tion at 0, given the constraint of positivity on τ1. The variance of this
distribution represents the tuning parameter and has to be set in such
a way to explore the parameter space and have a good acceptance rate,
see also Section 3.5. An analogous step is performed for τ2.
3. For g = 1, . . . , G we update the error variance σg using a Metropolis
step where the proposal distribution q(σoldg ;σ
new
g ) is a Gamma distri-
bution with parameters aσ and bσ. The proposed new value is then
accepted with probability:
min
[
f(Y|X(R),R, σnewg )pi(σnewg )q(σoldg ;σnewg )
f(Y|X(R),R, σoldg )pi(σoldg )q(σnewg ;σoldg )
, 1
]
. (3.10)
To obtain an efficient exploration of the parameter space with set aσ =
σoldg /bσ and bσ = e/σ
old
g , where e represents the variance of the proposal
distribution and can be set to obtain wished acceptance ratio.
Posterior inference can then be performed based on the MCMC output
using the marginal probabilities of the singles rgm’s.
The MCMC algorithm for the time-dependent coefficient model (3.7) is
pretty similar to the procedure described above, the main difference being
that at the first step we update either R, R′ or R′′. We then derive the
marginal posterior distribution f(Yg|X(R),R) for the time dependent model
obtaining:
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f(Yg|X(R),X∗2(R′),X∗3(R′′),R,R′,R′′, σg) = (2pi)−
n−kg
2 σ
−n
2
g c−kg−
k2g+k3g
2
ζ−
k2g+k3g
2 |Ag|− 12 |Cg|− 12
|Eg|− 12 exp[ 12σg qg]
Φkg(0;−E−1g Fg, σgE−1g ),
with
qg = Y
T
gYg −YT2gX2(R′)A−1g XT2(R′)Y2g −YT3gX3(R′′)C−1g XT3(R′′)Y3g
−F Tg E−1g Fg,
Fg = −XT(R)Yg +XT3(R)X3(R′′)C−1g XT3(R′′)Y3g +XT2(R)X2(R′)A−1g XT2(R′)Y2g
−σ1/2g c−11kg ,
Eg = XX
T −XT2(R)X2(R′)A−1g XT2(R′)X2(R) −XT3(R)X3(R′′)C−1g XT3(R′′)X3(R),
Ag = (X
T
2(R′)X2(R′) + (cζ)
−1Ik2g)
Cg = (X
T
3(R′′)X3(R′′) + (cζ)
−1Ik3g)
and YTg = (Y
T
1g,Y
T
2g,Y
T
3g); k2g and k3g are the number of selected β
′
gm and
β′′gm. We can now write the first step of the MCMC as:
1′. We first select which of the three matrices to update. We choose R
with probability λ and R′ (or R′′) with probability (1 − λ)/2. We
then use the same add/delete or swap scheme described above and we
accept the proposed Rnew (or R′new or R′′new). For R the acceptance
probability is:
min
[
f(Y|X(Rnew),X∗2(R′old),X∗3(R′′old),Rnew,R′old,R′′old)pi(Rnew|τ)
f(Y|X(Rold),X∗2(R′old),X∗3(R′′old),Rold,R′old,R′′old)pi(Rold|τ)
, 1
]
and similarly if R′ or R′′ is selected. Note that to perform this step
we need to use only the prior distribution of the selected matrix.
This algorithm can be run either without any constraint on the moves rel-
ative toR, R′ andR′′ or with the constraint that the elements ofR′ (orR′′)
71
can be selected only when the corresponding element of R is already selected
and that the elements of R can be eliminated only when the corresponding
element of R′ and R′′ are not selected. For our application we adopted the
constrain strategy. To implement this we do not need to add the ratio of
the proposal distributions into (3.8), since we use symmetric moves. This
choice, jointly with some empirical results (not reported here), led us to not
use the PicTar-Miranda information for the prior distribution of R′ and R′′,
because the selecting constraints imply that the prior probability of select-
ing the generic element r′gm (or r
′′
gm) already depends on the PicTar-Miranda
information through the prior probability on the corresponding element rgm.
This also implies a faster computational procedure in comparison with the
option of including the PicTar-Miranda information into the prior of R′ and
R′′.
3.5 Neural Tube Defects Application
We now apply our model to analyze the data described in Section 3.2, com-
bining miRNA and mRNA expression levels with sequence information. Our
model allows us to identify significant miRNAs for each target, possibly along
the time.
3.5.1 Parameter Settings
We first need to set the values of the hyperparameters of the model. A
normal distribution with variance σ2 corresponds to a normal truncated at
zero with variance ≈ 0.7σ2. The parameter c of the prior distribution of
the regression coefficients βgm can be interpreted as a correction factor. We
therefore decided to set c = 0.7. To complete the specification of the prior
distribution on σg we set δ = 3, obtaining a distribution centered on half
the sample variance of Yg, expecting our model to be able to explain around
50% of the variability of the data.
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In our variable selection framework, the parameter η of the Bernoulli
distribution (3.6) reflects the prior belief about the percentage of significant
coefficients in the model. In this application, having 23 regressors for each
of the 1,573 equations, we set η = −2.5 to obtain a prior expected number
of regressors between 1 and 2. For the more computational expensive time
dependent model we set η = −2.5 and ηb = 0.05, to avoid memory prob-
lems. We also set the hyperparameters aτ = 1.5 and bτ = 0.2 to obtain
a Gamma distribution that gives high probability to a broad set of values
of τ1 and τ2, taking into account the scale of values that come from PicTar
and Miranda algorithms. However the posterior distributions we obtained,
in all the different chains we ran, showed that this parameter setting is not
strongly informative. When running MCMC’s we have set the variance of the
truncated normal proposal distribution of τ1 and τ2 equal to 0.01 to obtain
a acceptance rate close to 25%.
We ran two different chains for each of the four possible combinations,
the time invariant model for the control and the hyperthermia group and
the time dependent model for the control and hyperthermia group. We used
either adding/deleting or swapping moves with equal probability at each step
of the chain; we assigned a probability of λ = 0.5 to the move that updates
R and then probability 0.25 to each of the moves that update R′ and R′′.
In all cases, after the initial burn-in, both chains mostly explored the same
region of the parameter space corresponding to configuration of R with high
posterior probability. In general, we found good agreement between the two
chains, which were run from different starting points. To be more precise,
correlations between the posterior probabilities of the two chains ranged from
0.84 to 0.88.
Figure 3.3 gives the summary trace plots for the number of selected coeffi-
cients βgm and corresponding log-posterior probabilities for the time invariant
model on the control group. In this case the chain was run for one million
iterations, from a starting randomly chosen set of 1,000 arrows, and mostly
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Figure 3.3: Trace plot for number of selected arrows and for the log-posterior
probability for the time invariant model
visited models with roughly 1,500 edges, i.e., on average almost 1 edge per
gene, a number not too far from the prior specification.
3.5.2 Results
The huge number of potential coefficients in the model implies that the weight
of a single coefficient toward the posterior probability of the entire model can
be potentially very small. Also, due to sparsity there may be many models
with almost the same (small) posterior probability. Because of this, it is
good practice to perform posterior inference based on the marginal posterior
probability of the single coefficients, rather than on their joint distribution.
These posterior probabilities of the presence of single interactions, that is,
P (rgm = 1|Y ,X) can be estimated directly from the MCMC samples by
taking the proportion of MCMC iterations for which rgm = 1.
The small sample size of our experimental groups does not allow us to
74
create a validation set, and therefore all the samples are used to fit the model.
Selected models are then evaluated based on the R2 statistic, calculated using
the posterior mean of regression coefficients.
As expected, when more covariates are included into the model, based
on their posterior probabilities, the statistics R2 increases, indicating that
the ordering created by the posterior probabilities correctly indicates the
significative variables. For the time invariant model a threshold of 0.15,
corresponding to 1,720 included edges, gave an R2 of 0.31, for the control
group, and of 0.32 for the hyperthermia group, with 1,864 included edges.
An identical behavior was observed for the additional coefficients of the time
dependent model, i.e., when the number of included β′’s and β′′’s increases
then the quality of the fitting improves; with a threshold of 0.15 for β’s and
a threshold of 0.5 for β′’s and β′′’s we obtain a R2 = 0.32 for the control
group, including 1,919 β’s, 164 β′’s and 165 β′′’s, and a R2 = 0.37 for the
hyperthermia group, including 2,053 β’s, 210 β′’s and 210 β′′’s.
In an effort to assess whether our model correctly selects miRNAs that
under-regulate targets gene, we also calculated the ordinary least square es-
timates of the regression coefficients and checked how many of them were
negative, see Appendix B for the calculation of the OLS estimates. Notice
that this approach does not impose the negative constraint on β’s. By in-
cluding all coefficients with posterior probability greater than .2 we obtain
that, 96.0% and 96.3% of the coefficients, for the control and hyperthermia
group, respectively, were correctly negative.
By exploring the regulatory network as a function of the posterior proba-
bility of the arrows we found that, for the time invariant model on the control
group, a posterior probability cut-off of 0.8 selected 43 arrows between 41
target genes and 11 miRNAs. These correspond to an expected rate of false
detection (Bayesian FDR) of 10.5%, that we calculated, following Newton
et al. (2004), as
FDR = C(κ)/|Jκ|
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where C(κ) =
∑
g,m ψgmI[ψgm≤κ] and ψgm = 1− P (rgm = 1|Y ,X), with |Jκ|
the size of the list (|Jκ| =
∑
g,m I[ψgm≤κ]). We set κ = 1 − k with k the
chosen threshold (i.e., 0.8). For the hyperthermia-treated group, the same
cut-off led to 59 selected arrows, between 59 target genes and 6 miRNAs,
corresponding to a a Bayesian FDR of 8.9%. Increasing the cut-off value to
0.9 identified 20 target genes and 7 miRNAs (corresponding to 22 arrows,
with a Bayesian FDR of 5.3%) in the control group and 31 target genes and
4 miRNAs (corresponding to 31 arrows, with a Bayesian FDR of 3.8%) in
the hyperthermia group.
Figure 3.4, produced using GraphExplore of Wang et al. (2004), displays
the selected network for the control group using a threshold of 0.8 on the
posterior probability under the time invariant model. A close look at the
pairs of target genes and miRNAs with high posterior probabilities reveals
that some of the regulatory relationships seem plausible and warrant future
investigation. Using a posterior probability cut-off of 0.9 for both time-
dependent and independent analysis of control-treatment data, 7 miRNAs
(miR-32, 181d, 213, 223, 299-5p, 367, 375) had at least one target gene for
a total of 70 gene targets. The same cut-off for both time-dependent and
independent analyses of hyperthermia data produced four miRNAs (miR-
142-3p, 299-5p, 367, 423) with at least one target gene for a total of 45 genes.
Overall there were 9 miRNAs and 86 gene targets identified with posterior
probability of at least 0.9. Of the 107 miRNA-gene target associations with
a posterior probability of at least 0.9, 10 were predicted by Miranda only, 2
by PicTar only, and 7 by both Miranda and PicTar. 70 of the gene targets
identified were associated with miR-367, a pluripotency-specific marker in
human and mouse ES cells, Li et al. (2009). MiR-367 expression steadily
decreased over time in control and hyperthermia-treated embryos, which is
consistent for a marker of pluripotency in a differentiating embryo. Also, 20
of the gene targets were associated with miR-299-5p, which has been shown
to regulate de novo expression of osteopontin, a protein that plays a role in
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Figure 3.4: Selected network for the control group using a threshold of 0.8
on the posterior probability
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enhancing proliferation and tumorigenicity, Shevde et al. (2009). The gene-
miRNA associations identified by our methods are potentially interesting for
follow-up NTD studies.
It is also interesting to look at the inference on the regression coefficients.
Figure 3.5 shows the estimates of the significant βgm’s for the time invariant
model under hyperthermia condition. Each bar in the plot represents the
1,573 regression coefficients for one of the 23 miRNAs. Non-zero values
correspond to the posterior mean estimates of the best βgm’s with posterior
inclusion probability above 0.15 (all other β’s are estimated by zero). Notice,
for example, how miRNAs miR-423, corresponding to the 22nd bar, and miR-
375, corresponding to the 16th bar, play an important role into the down-
regulatory mechanism.
Let us finally comment on the posterior inference on τ1 and τ2. These
parameters measure the influence of the prior information on the posterior
inference. Posterior inference on these parameters depends on the value given
to η. When selecting edges the hyperparameter η represents the weight as-
signed to the data and, consequently, τ1 and τ2 play the role of the weight
of the prior sequence information derived from the PicTar and Miranda al-
gorithms, respectively. The bigger the value of η the more the posterior
distribution of τj will be concentrated around small values. Besides this gen-
eral rule, inference on the τj’s generally depends on the concordance between
data and prior information, the number of observations and the number of
parameters in the model. According to our results, information extracted
from PicTar plays a much bigger role than the one from Miranda. With
η = −2.5, the posterior distribution of τ , for the control group, is concen-
trated around values that imply a 12% increase on the prior probability of
rgm = 1 for edges with corresponding high PicTar scores. For the hyper-
thermia group the corresponding percentage is 14%; when using the time
dependent model the prior probability of rgm = 1 increase by 13% and 15%,
respectively for the control and hyperthermia group. The behaviour of the
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Figure 3.5: Estimation of the significant βgm for the time invariant model
under hyperthermia condition
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Figure 3.6: Density Kernel estimate using the not time dependent model for
the control group
posterior distribution of τ1, setting different values of η, is summarized in
Figure 3.6. The scale of the estimates compensates the very large values we
observe for some of the PicTar scores. We can clearly see how the posterior
distribution concentrates to bigger values when η decreases. With η = −3.5
the prior probability of rgm = 1 increase by 48% and, setting η = −4.5, the
probability of selecting edges with corresponding high PicTar scores is more
than 2 times bigger of the corresponding prior probability for edges with
sgm = 0.
3.6 Conclusions
We have proposed a Bayesian graphical modeling approach that infers the
miRNA regulatory network by integrating expression levels of miRNAs with
their potential mRNA targets and, via the prior probability model, with their
sequence/structure information. Our model is able to incorporate multiple
data sources directly into the prior distribution avoiding arbitrary prior data
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synthesis. We have used stochastic search variable selection methods to infer
the miRNA regulatory network. We have considered experimental data from
a study on a very well known developmental toxicant causing neural tube
defects, hyperthermia. The analysis has involved 23 mouse miRNAs and
a total of 1,573 potential targets. Our goal was to identify a small set of
potential targets with high confidence. Some of the pairs of target gene
and miRNA selected by our model seem promising candidates for future
investigation. In addition, the time-dependent model has achieved significant
improvement in the percentage of explained variance, only slightly increasing
the size of the selected model. Our proposed modeling strategy is general
and can easily be applied to other types of network inference by integrating
multiple data sources.
An interesting feature of our inference is the somehow poor concordance
of the prior information, i.e., PicTar and Miranda scores, with the data.
This phenomenon has been observed by other authors in models for data
integration. Wei & Li (2008), for example, attribute this to the fact that
our knowledge of biological processes is not complete and can potentially
include errors and therefore induce misspecified edges on the networks. They
also suggest to first check the consistency of the prior information with the
available data. In our case, if the correlation between a miRNA and a target
gene is very small we may want to remove the edge from the network. On the
other hand, given the limited number of observations typical of experimental
studies in genomics, it would seem important to retain as much, possibly
accurate, prior information as possible. This important aspect of models for
data integration certainly deserves future investigation.
Extensions and generalizations of our model are possible. One future av-
enue we intent to pursue is trying to relax the assumption on the conditional
independence of the targets given the miRNAs. This assumption is necessary
in order to integrate out the covariance matrix, as in Brown et al. (1998b),
and still allow the selection of individual relations between a gene and a
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miRNA. Looking at this as a computational issue, it may be possible to still
sample the values of this huge covariance matrix in the MCMC, perhaps by
reducing the number of non-zero elements via the prior information on the
gene network.
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Appendix A
MCMC scheme for sampling (θ, γ)
We now describe the MCMC steps for (θ, γ) in more detail. For interpretabil-
ity, as previously described, no empty pathways or orphan genes are proposed
during sampling and, for identifiability, selecting the same set of genes for
different pathways is not allowed. At each iteration, only one pathway and/or
a gene are proposed to be added or removed.
(1) Change inclusion status of both gene and pathway – randomly choose
between addition (move 1.i in Figure 2.2) or removal(1.ii).
(1.i) Add a pathway and a gene:
First select a pathway that is not included in the model and has
none of its member genes in the model (θoldk = 0 and p
old
kγ = 0).
Randomly choose one gene from the pathway (γoldj = 0) and pro-
pose including both the pathway and the gene, i.e., set θnewk =
1, γnewj = 1. The move is accepted with probability
min
{
1,
f(θnew,γnew|T ,Y )
f(θold,γ old|T ,Y )
· pk·
∑K
r=1 I{θoldr =0,poldrγ =0}∑K
r=1 I{θnewr =1,pnewrγ =1,cond1,condId1}
}
, (11)
where cond1 and condId1 are explained in move type (1.ii) below.
(1.ii) Remove a pathway and a gene:
This move is the reverse of (1.i) described above. We first select
a pathway that is included in the model and has only one of its
83
member genes in the model (θoldk = 1 and p
old
kγ = 1). In addition,
this included gene (γoldj = 1) may not be the sole representative for
other included pathways, to ensure that no empty pathway is cre-
ated. Furthermore, identical sets of genes from different selected
pathways cannot be created. These constraints corresponds, re-
spectively, to cond1 and condId1 in the proposal ratios (11) and
(12). We attempt to remove both the pathway and the gene, i.e.,
set θnewk = 0, γ
new
j = 0 and accept the move with probability
min
{
1,
f(θnew, γnew|T , Y )
f(θold, γold|T , Y ) ·∑K
r=1 I{θoldr = 1, poldrγ = 1, cond1, condId1}
pk ·
∑K
r=1 I{θnewr = 0, pnewrγ = 0}
}
,
(12)
(2) Change the inclusion status of gene but not pathway – randomly choose
between addition (2.i) or removal(2.ii).
(2.i) Add a gene in an already included pathway:
First select a pathway already included in the model and that has
some member genes that could potentially be added (θoldk = 1 and
pk > p
old
kγ ). Let G be the set of pathways that satisfy these con-
ditions. Choose one of the non-included genes from this pathway
(γoldj = 0) and attempt to add it, i.e, set θ
new
k = θ
old
k = 1, γ
new = 1.
The proposal is accepted with probability
min
{
1,
f(θnew, γnew|T , Y )
f(θold, γold|T , Y ) ·∑K
r=1 I{θoldr = 1, pr > poldrγ } ·
∑
r∈G
1
p
new(cond2γ,condId2γ)
rγ∑K
r=1 I{θnewr = 1, pnewrγ > 1, cond2θ, condId2θ} ·
∑
r∈G
1
pr−poldrγ
 ,
(13)
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where ’cond2θ’, ’cond2γ’, ’condId2θ’ and ’condId2γ’ are explained
in move type (2.ii) below.
(2.ii) Remove a gene from an already included pathway:
This move is the reverse of (2.i) described above. We first select
a pathway already included in the model and that has more than
one of its member genes included in the model (θoldk = 1, p
old
kγ > 1).
In addition, at least one of the included genes from this pathway
may not be the sole representative for other included pathways
and its removal would not create an identifiability problem – this
corresponds to constraints ’cond2θ’ and ’condId2θ’in the proposal
ratios of (13) and (14). Once the pathway is selected, choose a
gene among the eligible candidates, that is, an included mem-
ber gene (γoldj = 1) which is not the sole representative for other
included pathways and whose removal does not create an iden-
tifiability problem – this corresponds to constraints ’cond2γ’ and
’condId2γ’. Constraints ’cond2θ’ for pathways, and ’cond2γ’ for
genes, will ensure that no empty pathways are created after the
proposed move. Leave the pathway status unchanged and attempt
to remove the selected gene, i.e., set θnewk = θ
old
k = 1, γ
new
j = 0.
The proposed move is accepted with probability
min
{
1,
f(θnew, γnew|T , Y )
f(θold, γold|T , Y ) ·∑K
r=1 I{θoldr = 1, poldrγ > 1, cond2θ, condId2θ} ·
∑
r∈G
1
pr−pnewrγ∑K
r=1 I{θnewr = 1, pr > pnewrγ } ·
∑
r∈G
1
p
old(cond2γ,condId2γ )
rγ
 .
(14)
(3) Change inclusion status of pathway but not gene – randomly choose
between addition (3.i) or removal(3.ii).
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(3.i) Add a pathway but leave genes’ status unchanged:
First select a pathway that is not included in the model but has
some of its member genes included in the model through other
pathways (θoldk = 0 and p
old
kγ ≥ 1). Attempt to add the pathway but
leave the status of its member genes unchanged, i.e., set θnewk = 1.
The proposed move is accepted with probability
min
{
1,
f(θnew, γnew|T , Y )
f(θold, γold|T , Y ) ·
∑K
r=1 I{θoldr = 0, poldrγ ≥ 1, condId3}∑K
r=1 I{θnewr = 1, pnewrγ ≥ 1, cond3}
}
,
where condId3 means that it is not possible to select a pathway
whose selected genes form the entire set of selected genes for an-
other selected pathway, and cond3 is explained in move type (3.ii)
below.
(3.ii) Remove a pathway but leave genes’ status unchanged:
This move is the reverse of (3.i) described above. First select a
pathway included in the model that has all of its poldkγ included
member genes associated with other included pathways (θoldk = 1
and ’cond3’). This will ensure that no orphan gene is created.
Attempt to remove the pathway but leave the status of the genes
unchanged, i.e., set θnewk = 0 and accept the move with probability
min
{
1,
f(θnew, γnew|T , Y )
f(θold, γold|T , Y ) ·
∑K
r=1 I{θoldr = 1, poldrγ ≥ 1, cond3}∑K
r=1 I{θnewr = 0, pnewrγ ≥ 1, condId3}
}
.
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Appendix B
Posterior Inference on Regression Coefficients
If inference on regression coefficients is desirable, these can estimate either
via the posterior distributions or the least squares estimates. For model (3.1)
we have the following posterior distribution:
pi(βg|Y,X(R), ω2) ∼ HN+(UgCg, σgUg) (15)
whereHN+ indicates a kg-variate half-normal distribution that gives positive
probability only to vectors formed by elements bigger than zero.
For the more general time-dependent model we have the following poste-
rior distributions:{
pi(βg|Y,X(R), ω2) ∼ HN+(E−1g Fg, σgE−1g )
pi(β′′g |Y,X(R), ω2) ∼ N(J−1g Hg, σgJ−1g ),
(16)
with
Jg = X
T
3(R′′)X3(R′′) −XT3(R′′)X3(R)L−1g XT3(R)X3(R′′) + (ζc)−1Ik3g ,
Hg = Y
T
3gX3(R′′) + (Y
T
gX(R) −YT2gX2(R′)D−1g XT2(R′)X2(R) + σ1/2g c−11kg)
L−1g X
T
3(R)X3(R′′),
Dg = X
T
2(R′)X2(R′) + (ζc)
−1Ik2g ,
Lg = X
T
(R)X(R) −XT2(R)X2(R′)D−1g XT2(R′)X2(R).
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The posterior distribution of β′ has the same form as the posterior distribu-
tion of β′′. Using the least squares approach, instead, we obtain the following
equations for β, β′ and β′′:

βˆgLS = (X
T
(R)X(R))
−1XT(R)(Yg −X∗2(R′)β′g +X∗3(R′′)β′′g ),
βˆ′gLS = (X
T
2(R′)X2(R′))
−1XT2(R′)(Y2g −X2(R)βg),
βˆ′′gLS = (X
T
3(R′′)X3(R′′))
−1XT3(R′′)(Y3g −X3(R)βg),
and then
βˆgLS = K
−1
g [βˆgOLS − (XT(R)X(R))−1XT(R)(X∗2(R′)(XT2(R′)X2(R′))−1XT2(R′)Y2g
+X∗3(R′′)(X
T
3(R′′)X3(R′′))
−1XT3(R′′)Y3g)],
with
Kg = Ikg − (XT(R)X(R))−1XT(R)(X∗2(R′)(XT2(R′)X2(R′))−1XT2(R′)X2(R)
+X∗3(R′′)(X
T
3(R′′)X3(R′′))
−1XT3(R′′)X3(R)).
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